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ABSTRACT
Model-based Biomarker Detection and Systematic Analysis
in Translational Science. (May 2012)
Youting Sun, B.S., Tsinghua University
Co–Chairs of Advisory Committee: Dr. Edward R. Dougherty
Dr. Ulisses Braga-Neto
This dissertation is concerned with the application of mathematical modeling
and statistical signal processing into the rapidly expanding fields of proteomics and
genomics. The research is guided by a translational goal which drives the problem
formalization and experimental design, and leads to optimization, prediction and con-
trol of the underlying system. The dissertation is comprised of three interconnected
subjects.
In the first part of the dissertation, two Bayesian peptide detection algorithms
are proposed to optimize the feature extraction step, which is the most fundamental
step in mass spectrometry-based proteomics. The algorithms are designed to tackle
data processing challenges that are not satisfactorily addressed by existing methods.
In contrast to most existing methods, the proposed algorithms perform deisotoping
and deconvolution of mass spectra simultaneously, which enables better identification
of weak peptide signals. Unlike greedy template-matching algorithms, the proposed
methods have the capability to handle complex spectra where features overlap. The
proposed methods achieve better sensitivity and accuracy compared to many popular
software packages such as msInspect.
In the second part of the dissertation, we consider modeling and assessing the
entire mass spectrometry-based proteomic data analysis pipeline. Different modules
iv
are identified and analyzed, resulting in a framework that captures key factors in sys-
tem performance. The effects of various model parameters on protein identification
rates and quantification errors, differential expression results, and classification per-
formance are examined. The proposed pipeline model can be used to aid experimental
design, pinpoint critical bottlenecks, optimize the workflow, and predict biomarker
discovery results.
Finally, the same system methodology is extended to analyze the workflow in
DNA microarray experiments. A model-based approach is developed to explore the
relationship among microarray data properties, missing value imputation, and sam-
ple classification in a complicated data analysis pipeline. The situations when it is
suitable to apply missing value imputation are identified and recommendations re-
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1CHAPTER I
INTRODUCTION
Translational science translates multidisciplinary scientific research into clinical prac-
tice with the goal of aiding diagnosis, discovering new drugs, developing more effective
treatments, and thus improving human health. Translational research may have dif-
ferent meaning to different researchers, but it seems important to almost everyone [1].
There are generally two paths in the practice of translational research. One
is data-driven and the other is goal-driven. The former tries to make sense of the
data, link the observed phenomenon with scientific explanations, or apply pattern
recognition to discover features that can be associated to phenotypes. The latter
follows the guidance of a goal, which usually leads to carefully designed experiments
and conceptualization of the translational problem [2]. In this dissertation, we adopt
the goal-driven approach, which is more of a systems engineering approach.
For “conceptualization”, a model-based approach is undoubtedly a beneficial way
to go as proved by the successful development and application of many well known
methods such as ANOVA for microarray data analysis [3], hypothesis testing for
biomarker detection, and controlling false positive identifications via decoy databases
in mass spectrometry (MS) based proteomics [4, 5]. The beauty of model-based ap-
proach lies in that by mathematical formalization of the problem, key issues and
factors can be captured, optimal solutions can be achieved, and the gained insights
can be translated into prediction or control of the underlying system. It should be
noted that the conceptualization should be formed at the right level of abstraction:
The model must be sufficiently complex to represent the characteristics or behaviors
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2of the physical system, while at the same time it must be simple enough that the
necessary parameters can be well estimated and the optimization problem is compu-
tationally tractable [2].
In translational science, most research is carried out on the molecular level which
study the fundamental building blocks of living organisms—DNA, RNA and protein
as well as their interactions. The terms “genomics” and “proteomics” were coined for
the two major branches concerning the study of genomes and proteins of organisms,
respectively. Ever since the the advent of DNA microarrays in the mid-1990s, the
development of related analytical equipments and methods has boomed. Microarray
and next generation sequencing for genome-wide gene profiling, mass spectrometry
for large scale protein analysis, along with other high-throughput technologies greatly
expand the experimental capabilities and propel the research.
In this chapter, the high-throughput technologies related to the research con-
ducted for the dissertation are briefly reviewed. The challenges in genomic and pro-
teomic data analysis and the problems with existing methods are outlined, which bring
forward the proposed methodology for biomarker detection and systematic analysis.
A. MS-based proteomics
Mass spectrometry is a key analytical tool in proteomics. It is widely used for large-
scale protein profiling with applications in biomarker discovery [6], signaling pathway
monitoring [7, 8], drug development, and disease classification [9]. A mass spectrom-
eter measures the concentration of ionized molecules at a range of mass-to-charge
ratios (m/z). MS instruments consist of three modules: an ionization source, a mass
analyzer and a detector which captures the ions and measures the intensity of each ion
species. Widely used ionization methods include electrospray ionization (ESI) [10] and
3matrix-assisted laser desorption/ionization (MALDI) [11, 12]. Mass analyzers sepa-
rate the ions according to their mass-to-charge ratios. There are several types of mass
analyzers including the Orbitrap [13], Quadrupole [14], Time-of-Flight (TOF) [15,16],
and Fourier transform ion cyclotron resonance (FTICR) [17].
In a typical MS experiment, unknown protein mixtures extracted from biological
samples are first digested into peptides by enzymes such as trypsin. Then peptides
enter a mass spectrometer where they get ionized and separated according to their
mass-to-charge ratios. As a result, a spectrum is produced which plots the ion inten-
sity against the mass-to-charge ratio. The recorded intensities reflect the abundance
or concentration of peptides. Liquid Chromatography (LC) is often coupled with
MS to achieve additional separation of peptides and thus reduce the complexity of
an individual mass spectrum: before entering the mass spectrometer, peptides are
first passed through an LC column where they are separated by the retention time,
depending on their physicochemical properties and interactions with the solvent. A
single LC-MS experiment usually produces hundreds to thousands of mass spectra
sampled during the LC elution process.
Analysis of LC-MS experiments by computational methods is challenging due
to the huge data size and rich information content, and moreover is complicated by
several facts including: (1) Proteins contained in complex samples such as plasma
and tissue extracts have a wide dynamic concentration range (e.g. 10 orders of mag-
nitude), plus peptides differ in ionization efficiencies, which means that the observed
peptide signal from MS data may also have a wide dynamic range. While high abun-
dance peptides are relatively easy to be identified, low abundance peptides/proteins,
which are often of more biological importance, are likely to be buried under noise
or interfering signals and thus hard to be detected [18]. (2) The shape of peptide
chromatographic peaks is not well predicted [19]. Due to experiment settings and the
4nature of the analytes, asymmetric shape or plateaus of chromatographic peaks may
be observed, which requires designed detection algorithms to be robust in tracking
signals from various peptide species and be adaptable across experiments. (3) A pep-
tide species may register several groups of peaks in different regions of the spectra
due to the following two points: first, a peptide species may take various numbers
of charges during ionization, therefore its peaks can be observed at different charge
states; second, at a given charge state, several peaks with equal spacing can be ob-
served due to heavy isotopes (e.g. 13C), which are commonly referred to as isotopic
peaks or the isotope series. Correctly identifying all the peaks and assigning them to
the right peptide is a non-trivial task. (4) The signal density can be very high even in
high-resolution LC-MS data and overlapping peptide peaks are commonly observed,
the detection of which is very challenging.
1. Feature extraction in MS data analysis
Peptide detection and identification, which extracts features from the raw spectra
and converts the raw data into a list of peptides, is usually the first step in MS
data processing. It is a critical step that directly affects the accuracy of subsequent
analysis, such as protein identification and quantification, data alignment between
multiple experiments, biomarker discovery, and sample classification.
Fragmentation spectra produced by tandem mass spectrometry (MS2) are fre-
quently used by popular software such as SEQUEST and Mascot [20] for database
searching to give peptide identifications. However, only a small percentage of peptides
present in the sample get selected for fragmentation analysis, and of these selected
peptides even fewer can be correctly identified by database searching due to spectrum
matching ambiguity or co-eluting precursor ions [21]. Furthermore, quantitation of
peptide abundance based on MS2 spectral counting is quite rough, and highly vari-
5able especially for low abundance peptides [22]. (Though by using well established
stable isotope labeling approaches such as tandem mass tags, the relative abundance
of analytes in different samples can be accurately determined [23].)
Therefore many algorithms for peptide detection are designed to use MS1 infor-
mation directly, and thus have the potential to identify more peptides. When mass
spectra have low resolution in which isotopic peaks cannot be baseline resolved (i.e.
the isotopic peaks convolve together to form isotope envelopes, and only one peak can
be observed for one peptide at a given charge state), and when peptides are singly
charged as commonly observed in MALDI, to report each detected peak as a peptide
feature might be sufficient, as done in [24–27]. But for high resolution spectra, report-
ing each observed peak as a unique peptide species would give rise to too many false
positives. Thus a variety of algorithms for deisotoping and charge states deconvolution
have been proposed. Such algorithms can be mainly divided into two categories: one-
dimensional (1D) algorithms (e.g. NITPICK [28], PepList [29], Decon2LS [30] and
Hardklo¨r [31]), which perform peak picking, deisotoping and charge state assignment
on a scan-to-scan basis, and two-dimensional (2D) algorithms (e.g. MZmine [32],
SpecArray [18], msInspect [33], SuperHirn [34], VIPER [35], MaxQuant [36], and
OpenMS [37]), which capture the 2D nature of LC-MS data and utilize informa-
tion from both the mass-to-charge and retention-time (RT) dimensions for peptide
detection. 2D algorithms appear to be more promising in handling LC-MS data.
Regardless of category, most of the aforementioned algorithms are grounded on the
idea of greedy template-matching which makes them ineffective to detect overlapping
and low abundance peptides. This motivates the development of a global optimiza-
tion based Bayesian peptide detection algorithm for feature extraction and peptide
detection.
62. MS analysis pipeline for biomarker discovery
In clinical applications of mass spectrometry, the number of samples available is
usually in the range of tens to a few hundred (small sample size). The samples
are analyzed by an MS instrument and transformed into a series of mass spectra
containing hundreds of thousands of intensity measurements with signal generated by
thousands of proteins/peptides (large feature dimension). This small-sample, high-
dimensionality problem requires the experiment and analysis to be carefully designed
and validated in order to arrive at statistically meaningful results.
The MS analysis pipeline consists of many steps, including sample preparation,
instrument analysis, feature extraction, quantification, statistic analysis and so on.
The pipeline can be viewed as a noisy channel, where each processing step introduces
some loss or distortion to the underlying signal and the biomarker discovery results are
affected by the combined effects of all upstream steps. While individual components
of the MS pipeline have been studied at length, little work has been done to integrate
the various modules, evaluate them in a systematic way, and focus on the impact
of the various steps on the end results of differential analysis and sample classifica-
tion. In real experiments, it is not easy to decouple the compound parameter effects
and determine the marginal influence of various modules on the end results, due to
variations and the complicated nature of the workflow. Moreover, owing to contam-
inants and unknown or incomplete ground-truth, it is hard to meaningfully evaluate
and compare results across different experiments. Thus we propose a model-based
approach to evaluate the pipeline systematically. It allows us to better understand
the characteristics of the MS data, the contributions of individual modules, and the
performance of the full pipeline.
7B. DNA microarray-based genomics
DNA microarrays are small, solid supports onto which the sequences from large num-
bers of genes are immobilized at fixed locations, known as probes. Based on probe-
target hybridization, the microarrays can be used to measure the expression levels
of hundreds and thousands of genes simultaneously. It revolutionizes the way scien-
tists examine gene expression, but also poses many challenges in the analysis of the
resulting high-dimension small-sample data sets.
Microarray data frequently contain missing values (MVs) because imperfections
in data preparation steps (e.g. poor hybridization, chip contamination by dust and
scratches) create erroneous and low-quality values, which are usually discarded and
referred to as missing. It is common for gene expression data to contain at least
5% MVs and, in many public accessible data sets, more than 60% of the genes have
MVs [38].
There exists many imputation methods for estimating MVs. But only a few
studies have examined the impact of MV imputation on high level analysis such
as sample clustering and classification. Furthermore, these studies are problematic
in key steps such as MV generation and classifier error estimation. To address these
problems, a model-based approach is developed to explore the relationship among the
data quality, MVs and high level analysis in the microarray data analysis pipeline.
C. Organization of the dissertation
This thesis is organized as described below.
Chapter II proposes a Bayesian approach, BPDA, for peptide detection in MS
data, such as MALDI-TOF and LC-MS, with high enough resolution [39]. BPDA is
based on a rigorous statistical framework and avoids problems, such as voting and
8ad-hoc thresholding, generally encountered in algorithms based on greedy template-
matching. It systematically evaluates all possible combinations of possible peptide
candidates to interpret a given spectrum, and iteratively finds the best fitting peptide
signal in order to minimize the mean squared error of the inferred spectrum to the
observed spectrum. In contrast to previous methods, BPDA performs deisotoping
and deconvolution of mass spectra simultaneously, which enables better identification
of weak peptide signals and produces higher sensitivity results. Unlike template-
matching algorithms, BPDA can effectively handle overlapping peptide features. Ex-
perimental results indicate that BPDA performs well on both simulated data and real
data, for various resolutions and signal to noise ratios, and compares very favorably
with commonly used commercial and open-source software.
Chapter III proposes a 2D Bayesian peptide detection algorithm, BPDA2d, which
extends the previous work [40]. BPDA2d is specially designed for LC-MS. It models
the spectra from both m/z and RT dimensions, thereby better capturing and fitting
the properties of LC-MS data. Instead of local template matching, BPDA2d performs
global optimization for all possible peptide candidates and systematically optimizes
their signals. Since BPDA2d looks for the optimal among all possible interpretations
of the given spectra, it has the capability in handling complex spectra where fea-
tures overlap. For each peptide candidate, BPDA2d takes into account its elution
profile, charge state distribution, and isotope pattern, and it combines all evidence
to infer the signal and existence probability of the candidate. By piecing all evidence
together — especially by deriving information across charge states — low abundance
peptides can be better identified and peptide detection rates can be improved. Our
experiments indicate that BPDA2d outperforms state-of-the-art detection methods
on both simulated data and real LC-MS data, according to sensitivity and detection
accuracy.
9While Chapter II and III focus on enhancing the feature extraction module in
the MS analysis pipeline, Chapter IV investigates the entire pipeline from a systems
point of view. A model-based approach is presented to integrate various pipeline
modules and evaluate the pipeline systematically, by means of simulation with ground-
truthed data [41]. Key steps and factors of the pipeline are captured, and their effects
on peptide identification rate, protein quantification accuracy, differential expression
results, and classification accuracy are studied. The proposed MS-based proteomics
framework can be used to optimize the workflow and predict experiment results.
Chapter V extends the system approach presented in Chapter IV to the analysis
of DNA microarray data. In this chapter, a model-based approach is developed to
examine the effects of MVs and their imputation on classification in a complicated
microarray data analysis pipeline [42]. Six popular imputation algorithms, two feature
selection methods, and three classification rules are considered. The situations when
it is suitable to apply MV imputation are identified and recommendations regarding
imputation are provided.
Chapter VI summarizes the dissertation and proposes future research directions.
D. Main contributions
The main contributions of this work are summarized below:
• Developed Bayesian peptide detection algorithms to optimize the feature ex-
traction step in MS-based proteomics. The algorithms can effectively identify
low abundance peptides and overlapping peptides, which is not satisfactorily
addressed by existing approaches. The proposed methods achieved better sen-
sitivity and accuracy results compared to many popular software packages.
• Designed a simulation framework for MS-based proteomics, which enables sys-
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tematic evaluation of the MS data analysis pipeline. By contrast, in previous
methods the pipeline is frequently chopped up into individual modules, and
is rarely studied and assessed as a whole from a systems point of view. The
proposed framework can be used to determine the working range of important
parameters, aid experimental design, predict the biomarker discovery results,
and to pinpoint critical bottlenecks which are worth investing resources into for
improving performance.
• Proposed a model-based approach to examine how different properties of a
microarray data set influence the quality of the imputed data and how missing
value imputation influence the classification performance. The results suggest
that it is beneficial to apply MV imputation when the noise level is high, variance
is small, or gene-cluster correlation is strong, under small to moderate MV rates.
In addition, an MV-rate related peaking phenomenon was uncovered.
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CHAPTER II
BAYESIAN PEPTIDE DETECTION FOR MASS SPECTROMETRY∗
A. Background
Feature extraction, which includes peptide detection and quantification, is usually
the first step in MS data processing pipeline. Accurate detection and quantification
of peptides and proteins is essential for biomarker discovery, drug development and
disease classification.
A variety of algorithms for peptide detection in high resolution mass spectra
have been proposed. Most of these algorithms are grounded on the idea of greedy
template-matching. Such algorithms include PepList [29], Decon2LS [30], Noy’s
method [43], MZmine [32], SpecArray [18], msInspect [33], SuperHirn [34], VIPER
[35], and OpenMS [37]. The templates used are often based on theoretic isotope pat-
terns calculated from peptide masses [44]. If an observed group of peaks matches the
proposed template well — the quality of the match is usually assessed by a fitting
score — it will be reported as a feature and then subtracted from the spectra. The
matching and subtraction process goes on until no more matches can be found. The
major problem with greedy template-matching is that it may be ineffective to detect
overlapping peptides. In the case of overlapping (e.g. one doubly charged peptide
can overlap with a singly charged peptide of half the mass given that the two elute
from chromatography column at a similar time), if the peak group of one peptide is
incorrectly matched and subtracted, the rest of the overlapping peptides cannot be
∗Reprinted with permission from “BPDA—a Bayesian peptide detection algo-
rithm for mass spectrometry” by Y. Sun, J. Zhang, U. M. Braga-Neto, and E.
R. Dougherty, BMC Bioinformatics, vol.11, pp. 490-500, 2010, Copyright 2010 by
BioMed Central.
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detected correctly using the remaining signal, which may result in error propagation.
Besides, each template is aimed at matching isotopic peaks of one single peptide,
and thus are likely to be different from the observed overlapping peaks, which ren-
ders a poor match and reduces the sensitivities of these algorithms. Alternatives to
greedy template-matching based approaches include 1D algorithms such as NITPICK,
which is based on non-greedy regression; Hardklo¨r, which approximates an isotope
peak cluster by a set of averagine models [45]. They also include 2D algorithms such
as MaxQuant, which mainly relies on the distance among isotope peaks and the cor-
relation between isotope labeled (SILAC) pairs to detect and quantify peptides in
SILAC-proteome experiments.
In this chapter, we propose a Bayesian Peptide Detection Algorithm (BPDA) to
optimize the workflow of peptide deisotoping and charge state deconvolution. BPDA
can be applied to data generated by MS instruments with mass resolutions high
enough to baseline-resolve isotopic peaks. It evaluates all possible combinations of
possible peptide candidates (originated from well-defined peaks of the raw spectrum
— see Methods section for more details) to interpret a given spectrum, and iteratively
finds the best fitting peptide parameters (peptide peak heights, existence probabili-
ties, etc.) in order to minimize the mean squared error (MSE) of the inferred spectrum
to the observed spectrum.
B. Methods
For 1D MS spectrum, we first perform spectrum preprocessing to remove the baseline,
filter the noise and generate a list of peptide candidates. Then BPDA is applied based
on the developed MS model to infer the best fitting peptide signals of the observed
spectrum, the results being peptide abundances, existence probabilities and so on.
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For 2D LC-MS spectra, we first detect peptide elution peaks along the retention
time dimension, and build elution peak groups by collecting the peaks which have
similar retention time together using a method similar to [46]. Each group contains
a series of consecutive spectra, which are then averaged to form a mean spectrum.
The rationale of using a mean spectrum to represent the group is that the noise
of consecutive spectra could be canceled out to a certain degree [24]. The BPDA
algorithm is then applied to each of the mean spectra, and finally an overall peptide
list is generated. The details of the preprocessing step, the proposed MS model, and
the BPDA algorithm are described in the following subsections.
1. Spectrum preprocessing and obtaining peptide candidates
A non-flat baseline is often observed in mass spectra, the presence of which can distort
the true signal pattern. Thus the first preprocessing step is to detect and subtract the
baseline from MS spectra. We use the minimum of a sliding window along the m/z
axis as the baseline, similar to the method used in [47]. The next step is peak detec-
tion. We use the Matlab function “mspeaks” (http://www.mathworks.com/access/
helpdesk/help/toolbox/bioinfo/ref/mspeaks.html) to perform this task. The
algorithm first identifies all local maxima in the wavelet denoised spectrum as puta-
tive peak locations. Then peaks are filtered based on their intensities and signal to
noise ratios. The last step of preprocessing is to obtain a list of peptide candidates.
Considering one detected peak with centroid at m/z value d, we want to find out
which peptides can potentially register a peak at this position. The answer is given
below in terms of the masses of such peptides:
mass = i(d−mpc)− j mnt, i = 1, 2, . . . , cs, j = 0, 1, . . . , iso, (2.1)
14
where mass is the mass of one peptide candidate, mpc is the mass of one positive
charge and mnt is the mass shift caused by addition of one neutron. Due to mass
defect, the mass shift varies for different elements. We approximate mnt using the
mass shift from 13C to 12C, which is 1.0034, since Carbon contributes most to the
isotope patterns. This approximation works well if the mass calibration of the instru-
ment is correct. The parameters cs and iso are user defined maximum numbers of
considered charge states and isotopic positions, respectively. It is easy to see from the
above equation that each detected peak gives rise to cs× (iso + 1) different peptide
candidates (masses). These candidates exhaust all the possibilities to generate the
peak with centroid d, but it does not follow that all the candidates really exist in
the sample. Therefore, our primary goal in peptide detection is to find the existence
probability of each peptide candidate. Also note that the total number of candidates
should be less than or equal to cs×(iso+1)×number of detected peaks, as is possible
that multiple peaks yield the same candidate mass.
2. Modeling the mass spectrum
Suppose N peptide candidates are obtained from the observed spectrum using the
method described in the previous section. Each candidate can generate a series of
peaks over different charge states, and at each charge state several isotopic peaks can
be registered. The signal generated by the kth peptide candidate is thus modeled by
the following equation, in which i and j represent the charge state and the isotopic






ck,ijf(xm; ρk,ij, αk,ij), m = 1, 2, . . . ,M, (2.2)
where the peak shape function is given by f(xm; ρk,ij, αk,ij) = e
−ρk,ij(xm−αk,ij)2 .
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That is, the peak is modeled as Gaussian-shaped, as in [19]. It is reported that the
Gaussian-shaped peak approximates the reality well enough to obtain good detection
results [43]. Still, this peak shape function can be adjusted for different instruments
without affecting the overall structure of the algorithm.
The observed spectrum is a mixture of the signal generated by the N peptide












ck,ijf(xm; ρk,ij, αk,ij) + m, (2.3)
m = 1, 2, . . . ,M.
In the above three equations, xm is the mth mass-to-charge ratio (m/z) in the
spectrum, ym is the observed intensity at xm, M is the number of observations, and
m is Gaussian random noise with zero mean and standard deviation σ. The value
of σ can be approximated by the standard deviation of the background region in the
spectrum. Note that we model m as additive Gaussian which is generally a good
model for the thermal noise in electronic instruments. There are reports of non-
Gaussian noise in FTMS [48] and thus it is safer to apply the proposed algorithm to
TOF MS instruments [49]. The parameters of the kth candidate, namely, αk,ij, ρk,ij,
λk and ck,ij are discussed in detail below:
• αk,ij is the theoretic centroid (m/z value) of the peak generated by candidate
k, at charge state i and isotopic number j.
αk,ij =
massk + impc + j mnt
i
, i = 1, 2, . . . , cs, j = 0, 1, . . . , iso, (2.4)
where massk is the mass of the kth candidate. Since the candidate’s mass is
already obtained, αk,ij can be calculated.
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• ρk,ij relates to the shape (width) of the peak centered at αk,ij. It can be es-
timated by using its relationship to the peak’s Full Width at Half Maximum
(FWHM): ρk,ij = 2
√
2 ln 2/FWHM.
• λk is an indicator random variable, which is 1 if the kth peptide candidate truly
exists in the sample and 0 otherwise.
• ck,ij is the height (i.e. intensity) of the peak generated by peptide k, at charge
state i and isotopic number j.
In summary, the model considers peaks at different isotopic positions and charge
states simultaneously for each peptide candidate, incorporating candidates’ existence
probabilities and the spectrum thermal noise.
3. Bayesian peptide detection
Let
θ , {λk, ck,ij; k = 1, . . . , N, i = 1, . . . , cs, j = 0, . . . , iso}
be the set of all the unknown model parameters. The goal of our algorithm is to
determine the value of θ based on the observed spectrum y = [y1, . . . , yM ]
T . In fact,
the value of λk is of our prime interest for the peptide detection problem. For this
purpose, we can use a Bayesian approach to first obtain the a posteriori probability
(APP) of all the parameters, P (θ|y). Then the APPs P (λk|y), k = 1, . . . , N, can be
obtained by integration of the joint posterior distribution P (θ|y) over all parameters
except λk. Clearly, the calculation involves high dimension integration which is not an
easy task. Besides, due to the highly nonlinear nature of the data model, none of the
desired APPs can be obtained analytically. To overcome the computational obstacle,
we resort to the Gibbs sampling method [50], which is a variant of the Markov Chain
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Monte Carlo (MCMC) approach [51], to sample the model parameters.
Gibbs sampling is an iterative scheme, which uses the popular strategy of divide-
and-conquer to sample a subset of parameters at a time while fixing the rest at the
sample values from the previous iteration, as if they were true. In other words, for
the lth parameter group θl, we sample from the conditional posterior distribution
P (θl|θ−l,y), where θ−l , θ \ θl. After this sampling process iterates among the
parameter groups for a sufficient number of cycles (which is referred to as the “burn-
in” period), convergence is reached. The samples collected afterwards are shown to
be from the marginal posterior distribution P (θl|y), which is independent of θ−l, and
thus these samples can be used to estimate the target parameters.
The Gibbs sampling process for the kth peptide candidate and the derivations
of the conditional posterior distributions of important model parameters are detailed
below.
a. Sampling the peak height vector
The heights of all the possible peaks (over different charge states and isotopic posi-
tions) of the kth peptide candidate are included in the peak height vector ck, which
is defined as ck , [ck,ij; i = 1, . . . , cs, j = 0, . . . , iso]T . By the Bayesian principle,
the conditional posterior distribution of ck is proportional to the likelihood times the
prior:
P (ck |y,θ−ck ) ∝ P (y|θ)Prior(ck), (2.5)
where θ−ck , θ \ ck.
It is easy to show the likelihood satisfies
P (y|θ) ∝ exp {− 1
2σ2
(y −Gλ(0) − λkHkck)T IM×M(y −Gλ(0) − λkHkck)}, (2.6)
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where
λ(s) , [λ1, . . . , λk = s, . . . , λN ]T , s ∈ {0, 1}, (2.7)
G =

g1(x1) g2(x1) . . . gN(x1)














ck,ijf(xm; ρk,ij, αk,ij) representing the signal
at m/z value xm generated by peptide candidate k. In addition,
Hk = [hm,(i−1)×(iso+1)+j+1]M×cs(iso+1), with hm,(i−1)×(iso+1)+j+1 =
f(xm; ρk,ij, αk,ij) = e
−ρk,ij(xm−αk,ij)2 .
The heights of the isotopic peaks of peptide candidate k at charge state i fol-
low a multinomial distribution [52], which by the Central Limit Theorem can be
approximated by a Gaussian distribution as below:
P (ck,ij, j = 0, . . . , iso |ak, ηk,i,pik ) = MN(akηk,i,pik) (2.9)
≈ N(akηk,ipik,
akηk,i[diag(pik)− piTk pik]), (2.10)
where ak is the total centroid intensity of candidate k, and ηk , [ηk,1, ηk,2, . . . , ηk,cs]T
and pik , [pik,0, pik,1, . . . , pik,iso]T denote the charge state distribution and the theoret-
ical isotopic distribution of peptide candidate k, respectively.
Thus the prior distribution of the peak height vector ck is given by:











Σck = diag(Σi), (2.13)
with
Σi = akηk,i[diag(pik)− piTk pik], i = 1, 2, . . . , cs. (2.14)
Substituting Eq. 2.6 and Eq. 2.11 into Eq. 2.5 and it can be shown by algebraic
manipulations [53] that the conditional posterior distribution of ck is also Gaussian,
with the mean vector and covariance matrix given below:
Σck|y,θ−ck = (I−KHk)Σck , (2.15)
µck|y,θ−ck = µck + K(y −Gλ
(0) −Hkµck), (2.16)







is known as the Kalman gain matrix
[54].
b. Sampling the total centroid intensity
The total centroid intensity of candidate k is denoted by ak, whose conditional dis-
tribution takes different forms for different values of λk.
When λk = 1 (the kth candidate is inferred to be present), by definition,





ck,ij · Ick,ij>0. (2.17)
When λk = 0 (the kth candidate is inferred to be absent), the distribution of ak,
which is independent of the observation ck, is modeled by a uniform distribution as
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below:
P (ak |ck,ij, λk = 0) = Unif(0, uk), (2.18)
where uk is the upper bound of ak.
c. Sampling the charge state distribution
Let ηk , [ηk,1, ηk,2, . . . , ηk,cs]T denote the charge state distribution of peptide can-
didate k. Unlike the isotopic distribution, the charge state distribution cannot be
theoretically predicted even when the peptide sequence is given. Thus ηk needs to
be estimated by the Gibbs sampling process. Let bk , [bk,1, bk,2, . . . , bk,cs]T , where
bk,i is the total centroid abundance of peptide k at charge state i. Given the charge
state distribution and the total centroid abundance of peptide k, the likelihood of bk
is multinomial:
P (bk|ηk, ak) = MN(ak,ηk). (2.19)
As is well known, the conjugate prior to a multinomial likelihood is Dirichlet,
which is also a reasonable choice for the prior of ηk. Thus, let the prior of ηk be
a Dirichlet distribution with parameter wα, where w is a weight parameter that
controls the strength of the prior information. A small w is preferable if uncertainty
resides in the prior, and vice versa. Then the posterior distribution of ηk is given by
P (ηk |bk ) ∝ P (bk |ηk )Prior(ηk) (2.20)
= Dirichlet(wα+ bk). (2.21)
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d. Sampling the peptide existence indicator variable
The conditional posterior distribution of λk, the existence indicator variable of peptide
k, is given by
P (λk |y,θ−λk ) ∝ P (y |θ )Prior(λk)
∝ exp {− 1
2σ2
‖y −Gλ‖2}Prior(λk), (2.22)
where G is defined in Eq. 2.8.
The log-likelihood ratio (LLR) of λk can be calculated as below
LLRλk = ln
P (λk = 1 |y,θ−λk )
P (λk = 0 |y,θ−λk )
= − 1
2σ2
(‖y −Gλ(1)‖2 − ‖y −Gλ(0)‖2) + ln P (λk = 1)
P (λk = 0)
, (2.23)
where λ(s), s ∈ {0, 1} is defined by Eq. 2.7.
If no prior knowledge is available about which peptide candidates are more likely
to be present in the sample, then a reasonable choice for the prior of λk could be
the uniform distribution. Therefore the last term in Eq. 2.23 can be dropped. The
conditional posterior distribution of λk is then obtained based on the log-likelihood
ratio as follows:




P (λk = 0 |y,θ−λk ) = 1− P (λk = 1 |y,θ−λk ). (2.25)
The complexity of the proposed Gibbs sampling algorithm is determined by two
factors: (1) the sheer number of peptide candidates, and (2) the correlation between
parameters that need to be sampled. The algorithm complexity grows exponentially
with the number of peptide candidates, and the correlation between parameters re-
duces the sampling efficiency. To address these two issues, we first partition non-
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overlapping peptide candidates into different groups. The proposed algorithm can be
applied to each group in a parallel manner and the algorithm complexity is reduced,
because within each group the number of candidates is reduced, and the corresponding
signal-containing spectrum region is restricted. Peptide candidates within each group
are then clustered by the k-means clustering algorithm [55], the distance measure be-
ing the correlation between peptide candidate signals. Peptide candidates within
a cluster have strong correlations among each other, and their indicator variables
are sampled from the joint conditional posterior distribution. These two measures
improve the overall efficiency of the algorithm.
Samples taken after convergence can be used to estimate the target parameters.
Particularly, the existence probability of peptide k is calculated as
P (λk = 1|y) = 1




where r0 is the first iteration after convergence is reached, R is the total number of
iterations, and λrk is the sample value of λk in the rth iteration. The kth peptide
candidate is said to be detected if its existence probability P (λk = 1|y) is greater
than a predefined threshold.
C. Results
We report below the observed performance of BPDA, side by side with well-known
tools, such as OpenMS and Decon2LS, in a number of experiments using both syn-
thetic and real data.
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1. Synthetic data
It is difficult to evaluate the performance of a given detection method using real data
due to the existence of unpredictable contaminants and the unknown true composition
of the samples. The merit of using simulated data is that the ground truth is known
and thus algorithm evaluation can be carried out [19,49].
a. Synthetic 20-mix spectra with different abundance levels (SNRs)
First, to test the robustness of our algorithm, we generated MS data sets with different
signal to noise ratios (SNRs), using the method described in [19]. In fact, the mean
signal strength (i.e., peptide abundance) was varied while the noise level (i.e., the
mean and variance of the noise) was fixed. For each peptide abundance level a, a ∈
{500, 2500, 12500}, the simulation was repeated 50 times. In each repetition, 20 true
peptides (with abundance level a and masses randomly selected from a quality-control
Shewanella Oneidensis data set provided by PNNL (http://omics.pnl.gov) served
as the input of the data model given by Eq. 2.3. The charge state distribution of one
peptide was modeled by a binomial distribution, which was reported to approximate
the real data well [19]. The isotopic distribution was obtained for each peptide by
using the Averagine model [56] and the Mercury algorithm [44]. The output consists
of a simulated mass spectrum. BPDA was applied to obtain the peptide existence
probabilities and abundance results. Its performance was evaluated by the classic
Receiver Operating Characteristic (ROC) curve. To obtain the ROC curve, first a
series of detection levels τ ranging from 0 to 1 with 0.001 increments was selected.
Peptides with existence probabilities not less than τ were said to be detected at this
specific detection level. The True Positive Rate (TPR) and False Positive Rate (TPR)
were then calculated at each detection level as follows: TPR = TruePositive
TruePositive+FalseNegative
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and FPR = FalsePositive
FalsePositive+TrueNegative
. One ROC curve (each point on the curve was a
pair of TPR and FPR at one detection level) was plotted for each repetition. And the
averaged ROC curve for one abundance level was obtained by averaging all the ROC
curves corresponding to the same abundance level. We also applied OpenMS on the
same data sets — to do so, we first wrote the simulated MS data into a text file with
three columns specified by elution time, m/z, and intensity, respectively. Next, the
text file was converted to mzXML (which is a valid input file format for OpenMS) by
the FileConverter tool integrated in the OpenMS software package (http://open-ms.
sourceforge.net). Finally, OpenMS was applied on the mzXML file to give the
detection results including detected features and their qualities. The ROC results
given by the two algorithms for different abundance levels are shown in Fig. 1.
























Fig. 1. ROC results for synthetic 20-mix spectra with different abundance levels
a = 500, 2500 and 12500.
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b. Synthetic 10-mix spectrum with overlapping peptides
As noted before, overlapping peptide peaks can complicate the mass spectra and make
the detection problem much harder. Thus, we investigated the performance of BPDA
in the presence of overlapping peptides. A simulated 10-mix spectrum was generated
by 5 pairs of overlapping peptides with unique masses: 1264.279, 1266.383, 1382.247,
1388.367, 1293.323, 1294.345, 1312.441, 1313.451, 1327.386 and 1329.378 Da. The
detection results for the comparison between BPDA and OpenMS are summarized
in Table I. BPDA detected all 10 peptides when FPR = 0.1, with very small mass
deviations and quite accurate abundance results. Almost all charge states of the 10
true peptides were correctly reported, except for the highest charge state of the 5th
and the 9th peptides. These two charge states were missed because the corresponding
peptide signal was very weak. In contrast, when FPR = 0.1, OpenMS only detected
the 3rd, the 7th and the 9th peptides. And when FPR increased to 0.3, OpenMS
achieved its highest TPR (0.6). But it could detect only one pair of peptides (the
one with the least overlap) and missed one peptide in each of the other 4 pairs. Two
examples are given in Fig. 2 to illustrate the observed overlapping peptide signals
and the detection results. The abundance results given by OpenMS were not close to
those of the true peptides (although the total abundance of each overlapping pair was
not far away from the corresponding total abundance of the true peptides). In total,
18 out of 36 charge states were correctly detected by OpenMS for the 10 peptides,
while BPDA correctly detected 34 out of 36, a much larger number.
We remark that Decon2LS results are missing from both synthetic experiments
described previously because the synthetic data could not be loaded, causing the
program to crash (the data was contained in a mzXML file converted from a 3-
column text file by the OpenMS FileConverter tool, whose format was successfully
26
Table I. Results for the synthetic 10-mix data set with overlapping peptides. Intn,
CS and dM denote the normalized intensity, detectable charge states and the
mass deviation from the true mass, respectively. When FPR = 0.1, BPDA
was able to detect all 10 true peptides, while OpenMS detected only 3 peptides
(marked by *). OpenMS achieved its highest TPR (0.6) when FPR = 0.3.
BPDA OpenMS
True Mass (Da) / Intn / CS dM (Da) / Intn / CS dM (Da) / Intn / CS
1264.279 / 0.034 / 1-3 -0.0065 / 0.032 / 1-3 NA
1266.383 / 0.103 / 1-3 -0.0025 / 0.110 / 1-3 −0.0025 / 0.156 / 1-3
1382.247 / 0.171 / 1-4 0.0028 / 0.181 / 1-4 0.0031∗ / 0.228 / 1-3
1388.367 / 0.114 / 1-4 -0.0073 / 0.097 / 1-4 −0.0046 / 0.150 / 1-3
1293.323 / 0.006 / 1-3 -0.0081 / 0.007 / 1-2 NA
1294.345 / 0.008 / 1-3 -0.0124 / 0.008 / 1-3 0.0033 / 0.018 / 1-2
1312.441 / 0.229 / 1-4 0.0018 / 0.247 / 1-4 0.0019∗ / 0.334 / 1-4
1313.451 / 0.183 / 1-4 -0.0061 / 0.173 / 1-4 NA
1327.386 / 0.080 / 1-4 -0.0035 / 0.067 / 1-3 0.0061∗ / 0.114 / 1-3
1329.378 / 0.072 / 1-4 -0.0035 / 0.078 / 1-4 NA
27






































































Fig. 2. Illustration of overlapping peptides observed in the synthetic 10-mix spectrum.
(a) Overlapping peptide signals observed in m/z range 422-424.5, which is gen-
erated by monoisotopic masses 1264.28 and 1266.38 at charge state 3. OpenMS
missed the first one while BPDA detected both. (b) Overlapping peptide sig-
nals observed in m/z range 647-650.5, which is generated by monoisotopic
masses 1293.32 and 1294.35 at charge state 2. OpenMS missed the first one
while BPDA detected both.
verified against mzXML version 2.1). We contacted Decon2LS’s developers, but did
not hear from them in time to have the Decon2LS results included.
2. Real data
In this section we report results from experiments carried out with real MS data.
The test data and parameter files used for different software tools were provided on
the BPDA project website http://gsp.tamu.edu/Publications/supplementary/
sun10a/bpda. We stick mainly to the recommended parameter values while only
adjusted a few parameters such as mass range and detection level to adapt to each
data set.
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a. MALDI-TOF MS 7-mix spectrum
We tested BPDA on a MALDI-TOF MS 7-mix spectrum, which contained seven
standard peptides with monoisotopic masses 1045.535, 1295.678, 1346.728, 1618.815,
2092.079, 2464.191 and 3146.464 Dalton. The spectrum was collected on a Bruker
ultraFlex MALDI TOF in the reflectron mode. As stated before, MALDI mostly
generates singly charged ions, so we only considered charge state 1 in the test. Since
there were contaminants in the data set, the goal was to check whether a detection
algorithm could find all the seven true peptides. The detection results of BPDA,
Decon2LS, OpenMS, and the commercial software flexAnalysis developed by Bruker
Daltonics (http://www.bdal.de) are summarized in Table II. BPDA detected the
first six peptides with a mean (absolute) mass deviation 0.018 Da. Decon2LS missed
the fifth and the last peptides, and the five detected peptides were of a mean mass
deviation 0.013 Da. OpenMS missed the forth and the last peptides, and the five
detected peptides were of a mean mass deviation 0.025 Da. The commercial software
flexAnalysis missed the fifth and the last peptides, and the five detected peptides were
of a mean mass deviation 0.013 Da. It can be seen that for the detected peptides,
the four algorithms yielded similar intensity results. Only BPDA and OpenMS were
able to detect the fifth peptide which had the lowest abundance among the first
six peptides. And all methods failed to report the last peptide. Visual inspection
suggested that this peptide generated very weak signal and its abundance was about
one third of the fifth peptide.
b. High-resolution LC-MS data set MyoLCMS
The preparation of the MyoLCMS data set is detailed as below: the data set was
collected from an overnight tryptic digest of horse myoglobin. Capillary liquid chro-
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Table II. Results for the MALDI-TOF 7-mix data set. Intn and dM denote the nor-
malized intensity, and the mass deviation from the true mass, respectively.
True Masses BPDA OpenMS Decon2LS Bruker
(Da) dM (Da) / Intn dM (Da) / Intn dM (Da) / Intn dM (Da) / Intn
1045.535 -0.023 / 0.550 0.019 / 0.655 -0.021 / 0.615 -0.023 / 0.532
1295.678 0.003 / 0.173 0.026 / 0.232 0.002 / 0.168 -0.001 / 0.167
1346.728 0.017 / 0.053 0.040 / 0.070 0.013 / 0.050 0.011 / 0.052
1618.815 0.035 / 0.178 NA 0.024 / 0.137 0.022 / 0.202
2092.079 0.021 / 0.004 0.021 / 0.009 NA NA
2464.191 -0.012 / 0.042 0.020 / 0.034 -0.007/0.030 -0.009 / 0.047
3146.464 NA NA NA NA
matography mass spectrometry (cLC/MS) was performed with a splitless nanoLC-2D
pump (Eksigent), a 50 mm-i.d. column packed with 10 cm of 5 mm-o.d. C18 particles,
nanoelectrospray and a high-resolution time-of-flight mass spectrometer (MicrOTOF;
Bruker Daltonics). The cLC gradient was 2 to 98% 0.1% formic acid/acetonitrile in
172 seconds at 400 nL/min. Sample was injected at a concentration of 60 fmol/mL
with an injection volume of 10 mL (600 fmol injected on-column).
There were 172 spectra with a m/z range 44.9 to 3005. To apply BPDA, we
first grouped peptide elution peaks, as described in the Method section. A total of 17
groups were obtained, each containing 10-20 consecutive spectra. A mean spectrum
was generated for each group, and BPDA was then applied. The detection results of
BPDA, OpenMS, and Decon2LS, which was applied in conjunction with VIPER [35],
Table III. Results for the high-resolution LC-MS data set MyoLCMS
BPDA OpenMS Decon2LS
Number of detected monoisotopic masses (features) 1635 2176 823
Average number of charge states for each monoisotopic mass 2.40 1.28 NA
Protein coverage of the top 5% detected features (%) 76.6 29.2 2.0
Protein coverage of the top 40% detected features (%) 81.8 77.9 40.9
No. of horse myoglobin peptides reported in the top 5% detected features 15 3 1
No. of horse myoglobin peptides reported in the top 40% detected features 16 11 7
Mean mass deviation of horse myoglobin peptides 0.004 0.019 0.020
in the top 5% detected features (Da)
Mean mass deviation of horse myoglobin peptides 0.004 0.014 0.014
in the top 40% detected features (Da)
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are summarized in Table III (we also considered the method implemented in the
SpecArray package [29], but found it to be inferior to BPDA, OpenMS, and Decon2LS
— the results were then omitted for the sake of conciseness). The number of features
with unique monoisotopic masses detected by BPDA, OpenMS, and Decon2LS-Viper
were 1635, 2176 and 823, respectively. In fact, it is not very informative to evaluate the
performance of a detection algorithm solely based on the number of detected features,
because of the presence of contaminants and false positive detections. Therefore, we
focus on the top detected features yielded by each detection algorithm. Detected
features were ranked by quality in descending order. Different algorithms utilize
different quality metrics; for example, Decon2LS and OpenMS provide a quality score
which measures how well an observed isotope pattern matches the predicted isotope
pattern, while BPDA provides the peptide existence probability (see Eq. 2.26) as
the quality measure. For each detection algorithm, for a given percentage of top
detected features, we calculated the number of detected horse myoglobin peptides
and the protein coverage rate. Note that by in-silico digestion of horse myoglobin,
there are 39 tryptic peptides with less than 2 missed cleavage sites (19 of which do
not contain any missed cleavage sites). Ideally, we should compare algorithms with
known peptide composition in the sample and report protein coverage at different
false positive rates. However, due to possible peptide contamination in the sample
in any LC/MS experiment, actual peptide species presented in the sample are never
known and this prevents us from estimating the false positive rates on the reported
peptide list. As a result, the statistical significance of reported peptides by different
peptide identification algorithms cannot be evaluated and the only option left for
users in hope of obtaining a list of peptides with relatively low false positive rate is by
applying a percentage threshold on the quality score reported by different algorithms.
Thus, protein coverage v.s. percentage threshold on quality score is a meaningful
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measurement of the performance of peak detection algorithms and the results are
shown in Fig. 3. We need to point out that although the protein coverage of OpenMS
seems to be comparable with the proposed algorithm in regions where the quality
score percentage threshold is large, in such regions the reported peptide list may
contain a lot of false positives and it is not an indication of good or bad algorithm
performance. Instead, how quickly an algorithm reaches high protein coverage as the
percentage threshold increases should be the measurement of the performance. In
Fig. 3, we can see that BPDA reaches high protein coverage much faster than other
algorithms at low percentage threshold regions.































Fig. 3. Protein coverage results achieved by BPDA, OpenMS, and Decon2LS for the
LC-MS data set MyoLCMS.
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D. Discussion
We observed in our experiments that BPDA performs well on both simulated data
and real data, for various SNRs and resolutions, and in complex cases where features
overlap.
For the synthetic 20-mix experiment, we observe in Fig. 1 that the sensitivity
(i.e., TPR) of BPDA was consistently higher than that of OpenMS for each abundance
level, and both methods gave better sensitivity results as the abundance level (i.e.,
SNR) increased. Also it is observed that BPDA was quite robust for different SNRs.
For the synthetic 10-mix experiment with overlapping peptides, we saw that BPDA
detected all the peptides at a small false-positive rate FPR = 0.1, with very small
mass deviations and quite accurate abundance results, and nearly all the charge states
of the 10 true peptides were correctly reported. In contrast, at FPR = 0.1, OpenMS
could detect only a few of the peptides. The abundance results given by OpenMS
were not very close to those of the true peptides. Also OpenMS could only detect
about half of the charge states.
The results obtained with real data corroborated the findings made with the syn-
thetic experiments. For the MALDI-TOF MS 7-mix data, the four algorithms yielded
similar intensity results, but BPDA was the only one to detect six out of the seven
peptides. For the MyoLCMS experiment, we focused on protein coverage results,
which is an important criterion to determine the confidence in protein identification
and quantification [57,58]. It was observed that BPDA displayed the largest protein
coverage among the programs tested.
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CHAPTER III
BAYESIAN PEPTIDE DETECTION FOR LC-MS∗
A. Introduction
For peptide detection in LC-MS data, 2D algorithms which utilize information from
both the mass-to-charge and retention-time dimensions can better capture the fea-
tures in the data, and thus appear to be more promising compared to 1D algorithms
which perform peak picking, deisotoping and charge state assignment on a scan-to-
scan basis.
In this chapter, we present BPDA2d, a 2D Bayesian peptide detection algorithm
and an extension of BPDA, to process high-resolution LC-MS data more efficiently.
BPDA2d shares the core idea with BPDA, which is to systematically evaluate all
possible combinations of peptide candidates for spectra interpretation, and to opti-
mize all peptide signals in order to minimize the MSE between inferred and observed
spectra. The outputs include peptide monoisotopic mass, retention time, abundance,
existence probability, etc. BPDA2d essentially differs from BPDA by explicitly ex-
ploiting information residing in the RT dimension to analyze spectra and detect pep-
tides. While BPDA only models peptide signals along the m/z dimension, BPDA2d
models the spectra from both m/z and RT dimensions, thereby capturing and fitting
the properties of LC-MS data better.
BPDA2d offers following advantages over conventional methods:
(i) BPDA2d carries out global optimization instead of local template matching.
∗Reprinted with permission from “BPDA2d— a 2D global optimization based
Bayesian peptide detection algorithm for LC-MS” by Y. Sun, J. Zhang, U. M. Braga-
Neto, and E. R. Dougherty, Bioinformatics, vol. 28, pp. 564-572, 2012 Copyright
2012 by Bioinformatics.
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It is “global” in two senses: First, for the detection of one peptide candidate, BPDA2d
extracts all relevant information and observations (including isotopic peaks, charge
state distributions and LC elution peaks) that span all over the m/z-RT space, and
pieces all evidence together to infer the candidate’s existence probability. As a result,
low abundance peptides can be better identified. In contrast, existing algorithms
often perform peptide deisotoping at a single charge state, isolating useful information
that can be drawn from other charge states. While high abundance charge states
may be correctly detected, low abundance charge states might be missed or wrongly
assigned. Additional benefits of collating all charge states are discussed in [59] (though
their method requires the peak clusters at various charge states to have a moderate
correlation, and thus may not work efficiently if the shape of the peak cluster at
any charge state differs from other charge states due to the presence of interfering
peptides.) Second, BPDA2d performs global optimization for all candidates and
simultaneously finds their best fitting signals. Since BPDA2d looks for the optimal
among all possible interpretations of the MS spectra, the procedure is thus systematic.
In contrast, greedy template-matching based methods detect peptides one by one in a
greedy manner, which prevents them from evaluating all potential interpretations of
the given spectra and may lead to poor detection of overlapping peptides (See Results
section). Therefore, the results are often suboptimal.
(ii) BPDA2d provides existence probabilities for all the candidates considered, as
opposed to the fitting scores generally provided by greedy template-matching meth-
ods. The metrics used for fitting score calculation may be heuristic (e.g. KL dis-
tance [33]). In addition, the range of the fitting score may vary from experiment to
experiment, making it hard for the end user to interpret and to select a proper thresh-
old to filter out low quality features. On the contrary, existence probabilities given
by BPDA2d are derived based on a solid statistical framework and can be directly
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used for probability-based evaluation.
(iii) BPDA2d is flexible in the sense that it makes little assumptions about the
underlying spectra. When modeling peptide signals, the model is derived from obser-
vations as opposed to employing any pre-assumed peptide peak shape as in [37, 60].
Therefore, BPDA2d is more effective in tracking signals from various peptide species
and more adaptable across experiments.
(iv) Most parameters in the proposed method possess a clear physical meaning
as they come directly from observations of the mass spectra.
B. Methods
We first preprocess the spectra to remove baseline, filter noise, detect peaks in the
m/z-RT plane, and generate a list of peptide candidates annotated by mass and RT.
Then BPDA2d is applied based on the developed MS model to infer the best fitting
peptide signals of observed spectra, the results being peptide monoisotopic mass, RT,
abundance, existence probability, etc. Details of preprocessing steps, proposed MS
model, and BPDA2d algorithm are described in the following subsections.
1. Spectra preprocessing and obtaining peptide candidates
Non-flat baselines are often observed in mass spectra. Their presence can distort
the true signal pattern. Thus, the baseline of each MS scan is first identified as
the running minima along the m/z axis using a window size of 4 Dalton (a tun-
able parameter), and subtracted from the scan. Then each scan is smoothed by the
LOWESS regression method (Matlab mslowess function: http://www.mathworks.
com/help/toolbox/bioinfo/ref/mslowess.html) with Gaussian kernel and a span
of 9 consecutive points.
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The next step is 1D peak detection along the m/z axis. We followed the approach
implemented in the Matlab mspeaks function. Specifically, in each smoothed MS scan,
local maxima are first identified as putative peak locations. Then peaks are filtered
based on their intensities and signal to noise ratios (defined as the local maximum
divided by the minimum of the two neighboring local minima), and peaks that are
too close to each other (might occur due to over segmentation) are joined into a single
one. The thresholds used for intensity and over-segmentation filters, τintn and τseg,
respectively, are automatically determined depending on the characteristic of each
input MS scan as below:




, 7× lower 10% quantile of the space
between neighboring m/z values).
And the SNR threshold is a tunable parameter with default value 3.
Next, the detected 1D peaks in adjacent spectra are connected along the RT
dimension: 1D peaks are first sorted by their centroid m/z positions, and then divided
into disjoint subsets, in which the maximal m/z distance between two 1D peaks is
less than twice the smallest m/z in the subset times ∆m (a user defined mass error
in ppm). For each subset, the peaks are then sorted/connected according to their RT
positions (if multiple peaks have the same RT, only the one with the largest intensity
is retained). Next, the connected 1D peaks are split at RT gaps (a tunable parameter),
and the resulting so called elution peaks are smoothed by the LOWESS regression
method with a ±3 scan width. The elution peaks could be multimodal, which may
for instance be produced by two different peptides with partially overlapping elution
peaks, or by isomers with variant post-translational modifications and thus different
retention times. Multimodal elution peaks are split at local minima. A point is
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identified as a local minima/maxima if it is preceded by a local maxima/minima and
is followed by a value greater/lower by 15% (the threshold is a user tunable parameter
which should be comparable to the random intensity fluctuations of the instrument).
Consequently all elution peaks are now unimodal, which will be used to propose a list
of peptide candidates in the next step. For each elution peak, its centroid position in
the m/z axis is estimated as the average of the m/z values of the connected 1D peaks
weighted by their intensities. This method enables very accurate mass estimation, as
reported by [36].
Now, considering one elution peak with centroid at m/z value d, we want to find
out which peptide candidates can potentially produce this signal peak. At least two
conditions need to be satisfied. (1) The masses of such peptides should be restricted
to the following set:
{mass |mass = i(d−mpc)− j mnt,
i = 1, 2, . . . , cs, j = 0, 1, . . . , iso},
(3.1)
where mass is the mass of such a candidate, mpc is the mass of one positive charge
and mnt is the mass shift caused by addition of one neutron. Due to mass defect, the
mass shift varies for different elements. We approximate mnt using the mass shift from
13C to 12C, which is 1.0034, since Carbon contributes most to the isotope patterns.
But mnt is a user accessible parameter whose value can be changed as needed. The
parameters cs and iso are user defined maximal numbers of considered charge states
and isotopic positions, respectively. (2) The shapes of such candidates’ elution peaks
should resemble the aforementioned elution peak with centroid d (hereafter referred
to as the “source” elution peak). But in the presence of scan noise, missing values
or overlapping peptide signals, the actual shapes of candidates’ elution peaks can be
quite different from the observed shape of the source peak. Thus, in order to estimate
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candidates’ elution peaks more accurately, other elution peaks which can be produced
by such candidates need to be taken into account. In more detail, assume the source
elution peak has given rise to a candidate with mass value massk taken from the set
defined in Eq. 3.1. Then, theoretically, this candidate can generate a set of elution
peaks with centroids given by
αk,ij =
massk + impc + j mnt
i
,
i = 1, 2, . . . , cs, j = 0, 1, . . . , iso,
(3.2)
where αk,ij is the theoretic centroid (m/z value) of the elution peak generated by
candidate massk at charge state i and isotopic number j. In theory, the set of
elution peaks generated by this very candidate should have the same shape (up to a
multiplicative constant). Therefore, we search in the previous detected elution peaks
for those whose centroids are coincident with the values given by Eq 3.2 (within
∆m) and have correlation larger than 0.6 with the source elution peak, since these
elution peaks can serve as extra evidence to infer the candidate’s real elution peak.
Finally the candidate’s elution peak is estimated by taking the average of all identified
elution peaks weighted by the mean intensity of each elution peak involved in the
calculation. The candidate’s elution profile is then obtained by normalizing its elution
peak by the apex, and the corresponding RT of the apex is taken as the candidate’s
retention time. It is worth to mention that we do not assume any particular shape
for candidates’ elution profiles, but instead estimate them from relevant observations.
Due to heterogeneity of peptides and fluctuations in liquid chromatography, this
approach is more robust in the presence of noise and more adaptable across analysis
platforms compared to using any pre-defined model [37,60].
As can be seen from Eq. 3.1, each detected elution peak gives rise to cs× (iso+
1) different peptide candidates whose elution profiles have been estimated in the
39
previous step, but it does not follow that all these candidates really exist in the
sample. Therefore, our primary goal in peptide detection is to find the existence
probability of each peptide candidate. Also note that the total number of candidates
should be less than or equal to cs × (iso + 1) × (number of detected elution peaks),
as it is possible that multiple elution peaks yield the same candidate. It is worth to
mention that the way candidates are generated in BPDA2d is fundamentally different
from that in BPDA, as additional information carried by elution peaks is utilized.
Candidates are now associated with elution profiles in addition to mass values.
2. Modeling the mass spectra
We propose a complete model to capture the specific properties of peptides and mass
spectra over the entire m/z-RT plane.
Suppose N peptide candidates are obtained from the observed spectra using
methods described in the previous section. Each candidate can generate a series of
elution peaks over different charge states, and at each charge state several isotopic
peaks can be registered. Hence, the signal generated by the k-th peptide candidate
is modeled by Eq. 3.3, in which i and j represent the charge state and the isotopic
position of the candidate, respectively. The baseline removed and smoothed spectra
(see the previous section for details) are a mixture of signals generated by N peptide
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ck,ijlk(t)Ixm=αk,ij + (t), (3.4)
m = 1, 2, . . . ,M, t = 1, 2, . . . , T.
In the above two equations, xm is the m-th mass-to-charge ratio in the sig-
nal region, i.e., xm ∈ {m/z values of detected elution peaks}
⋃ {m/z values of all }.
{.candidates’ theoretic peaks }, t indexes spectra, M and T are the total number of
m/z values and spectra, respectively, y(xm, t) represents the intensity at point (xm,t),
I is an indicator function, IA = 1 if A 6= ∅, IA = 0 otherwise, and the noise term (t)
follows a Gaussian distribution with zero mean and standard deviation σ(t), which
is generally a good model for thermal noise in electrical instruments. The value of
σ(t) can be approximated by the standard deviation of the background region in the
t-th scan. The parameters of the kth candidate, namely, αk,ij, lk(t), λk and ck,ij are
discussed in detail below:
• αk,ij is the theoretic centroid position (in the m/z axis) of the elution peak
generated by candidate k, at charge state i and isotopic number j, the value of
which is given by Eq. 3.2.
• lk(t) is the normalized elution profile of the k-th peptide candidate, which is
already obtained in previous section.
• λk is an indicator random variable, which is 1 if the kth peptide candidate truly
exists in the sample and 0 otherwise.
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• ck,ij is the apex intensity of the elution peak generated by peptide k, at charge
state i and isotopic number j.
In summary, the model considers peptides’ elution peaks at different isotopic
positions and charge states simultaneously, incorporating candidates’ existence prob-
abilities and spectra thermal noise.
3. Bayesian peptide detection
Let θ , {λk, ck,ij; k = 1, . . . , N, i = 1, . . . , cs, j = 0, . . . , iso} be the set of all unknown
model parameters. The goal of our algorithm is to determine the value of θ based on
the observed spectra vector y = [y(xm, t);m = 1, 2, . . . ,M, t = 1, 2, . . . , T ]
T . It is not
an easy task since there are large number of parameters that need to be simultaneously
optimized. To overcome the computational obstacle, we resort to the Gibbs sampling
method [50] to sample model parameters. The Gibbs sampling process for the kth
peptide candidate and the derivations of the conditional posterior distributions of
important model parameters are detailed below.
a. Sampling the apex vector
The apex vector ck , [ck,ij; i = 1, . . . , cs, j = 0, . . . , iso]T incorporates all possible
elution peaks (over different charge states and isotopic positions) of the kth peptide
candidate. By the Bayesian principle, the conditional posterior distribution of ck is
proportional to the likelihood times the prior:
P (ck |y, θ−ck ) ∝ P (y|θ)Prior(ck), (3.5)
where θ−ck , θ \ ck.
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It is easy to show the likelihood satisfies
P (y|θ) ∝ exp {−1
2
(y −Gλ(0) − λkgk)TΣe−1(y −Gλ(0) − λkgk)}, (3.6)
where
y = [y(x1, 1), y(x1, 2), . . . , y(x1, T ), y(x2, 1), y(x2, 2), . . . , y(x2, T ), . . . ,
y(xM , 1), y(xM , 2), . . . , y(xM , T )]
T
(3.7)
is the observed denoised spectra vector.
λ(q) , [λ1, . . . , λk = q, . . . , λN ]T , q ∈ {0, 1}, (3.8)
is an indicator vector for peptide existence.
Σe = diag
(




1, . . . , σ
2
T ; . . . ;σ
2





with σ2t being the variance of the t-th spectrum.
G = (g1,g2, . . . ,gN), (3.10)
whose k-th column is given by
gk = [gk(x1, 1), gk(x1, 2), . . . , gk(x1, T ), gk(x2, 1), gk(x2, 2), . . . , gk(x2, T ), . . . ,
gk(xM , 1), gk(xM , 2), . . . , gk(xM , T )]
T ,
(3.11)





ck,ijlk(t)Ixm=αk,ij , m =
1, 2, . . . ,M , t = 1, 2, . . . , T, representing the signal at (xm,t) generated by peptide
candidate k.
The apexes of the elution peaks of peptide candidate k at charge state i follow
a multinomial distribution [52], which by the Central Limit Theorem can be approx-
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imated by a Gaussian distribution as below:
P (ck,ij, j = 0, . . . , iso |ak, ηk,i, pik ) = MN(akηk,i, pik) (3.12)
≈ N(akηk,ipik,
akηk,i[diag(pik)− piTk pik]), (3.13)
where ak is the total apex intensity of candidate k, ηk , [ηk,1, ηk,2, . . . , ηk,cs]T de-
notes the candidate’s charge state distribution, and pik , [pik,0, pik,1, . . . , pik,iso]T is the
theoretical isotopic distribution estimated by the Averagine approach [45,56].
Thus the prior distribution of the apex vector ck is given by:










Σck = diag(Σi), (3.16)
with
Σi = akηk,i[diag(pik)− piTk pik], i = 1, 2, . . . , cs. (3.17)
Substituting Eq. 3.6 and Eq. 3.14 into Eq. 3.5 and it can be shown by algebraic
manipulations [53] that the conditional posterior distribution of ck is also Gaussian,
with the mean vector and covariance matrix given below:
Σck|y,θ−ck = (I−KHk)Σck , (3.18)
µck|y,θ−ck = µck + K(y −Gλ
(0) −Hkµck), (3.19)
where Hk = [hms,(i−1)×(iso+1)+j+1]MT×cs(iso+1) is the elution profile matrix of candidate
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k. The [(i− 1)× (iso+ 1) + j + 1]th column contains the normalized elution profile
of candidate k at charge state i and isotopic number j which has been estimated in






is known as the Kalman
gain matrix [54].
Note that the matrices involved in the above equations have huge dimensions
which make the calculation almost infeasible. Thus, to update each peptide’s signal,
the related matrices K,G,H,y and Σe are restricted to the corresponding peptide
signal regions. This does no harm to the calculation accuracy while dramatically
increases the speed.
For the kth peptide candidate, its total apex intensity, ak, and its charge state
distribution, ηk, are updated from the corresponding conditional posterior distribution
derived in a similar manner as done in the previous chapter.
b. Sampling the peptide existence indicator variable
Let λk denote the existence indicator variable for peptide k. Its conditional posterior
distribution is given by
P (λk |y, θ−λk ) ∝ P (y |θ )Prior(λk)
∝ exp {−1
2
(y −Gλ)TΣ−1e (y −Gλ)}Prior(λk), (3.20)
where G is defined in Eq. 3.10.
The log-likelihood ratio (LLR) of λk can be calculated as below
LLRλk = ln
P (λk = 1 |y, θ−λk )




(y −Gλ(1))TΣ−1e (y −Gλ(1))− (y −Gλ(0))TΣ−1e (y −Gλ(0))
]
+ ln
P (λk = 1)
P (λk = 0)
, (3.21)
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where λ(q), q ∈ {0, 1} is defined by Eq. 3.8.
Absent prior knowledge about which peptide candidates are more likely to be
present in the sample, then a reasonable choice is a uniform prior for λk. However,
we wish to be conservative regarding the existence of peptide candidates. The idea
is that by adding more candidates, it is possible to reduce the MSE between the
inferred spectra and the observed denoised spectra, but at the same time the chances
of overfitting increases as the model becomes more complex. Thus, a prior based
on Bayesian information criterion (BIC) [61] is adopted to resolve the problem by
introducing a penalty term for the number of parameters of the model. And the










where ∆ = Card(θ)−Card(θ−λk,−ck) = Card(ck) is the difference between the num-
ber of free parameters of the two models – with and without candidate k, respectively.
The conditional posterior distribution of λk is then obtained based on the log-
likelihood ratio as given by Eq. 2.24 and 2.25.
For Gibbs sampling, it is well known that the correlation between parameters
can reduce sampling efficiency. Thus, we cluster peptide candidates which have large
overlaps in both m/z and RT dimensions together. Candidates within one cluster
have strong correlations among each other, and their indicator variables are sampled
from the joint conditional posterior distribution. The iteration order also affects the
performance. Therefore, peptide clusters are first sorted by their importance, which
is defined as the maximal intensity of the peptides in the cluster. The iteration
starts from the most significant cluster and continues to the next significant one.
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Our experimental results suggest that this scheme helps to reduce false positives and
speed up convergence. The pseudocode of the entire Gibbs sampling process is given
by Table IV. Samples taken after convergence can be used to estimate the target
parameters. The existence probability of peptide k is calculated by Eq. 2.26.
If the LC-MS data also contain MS2 fragmentation spectra, then MS1 detected
peptides can be linked to MS2 identified features given by software such as SEQUEST
to obtain peptide sequence information.
C. Results and discussion
We report the observed performance of BPDA2d, side by side with state-of-the-art
methods, such as msInspect and BPDA in a number of experiments using both syn-
thetic and real data. The efficiency of BPDA2d in detecting low abundance and
overlapping peptides is illustrated.
1. Results for synthetic data
a. Synthetic 100-mix LC-MS data sets with different abundance levels (SNRs)
First, to test robustness of various algorithms, we generated LC-MS data sets with
different SNRs using methods described by [19]. More specifically, the mean signal
strength (peptide abundance) was varied while the noise level (mean and variance of
noise) was fixed. For each peptide abundance level a ∈ {100, 500, 5000}, the simula-
tion was repeated 30 times. In each repetition, 100 true peptides (with abundance
level a and masses randomly selected from tryptic digested human proteins) served
as inputs of the model given by Eq. 3.4. The charge state distribution of one pep-
tide was modeled by a binomial distribution, which was reported to approximate the
real data well [19]. The isotopic distribution was calculated theoretically based on
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Table IV. The Gibbs sampling process
1. Cluster candidates into S clusters.
2. Sort clusters by their importance in descending order.
3. For iteration r = 1 toR
4. For cluster s = 1 toS
5. For peptide candidate k = is1 to i
s
Ns
6. Draw crk based on its conditional posterior distribution.
7. end of k loop
8. Draw λrk, k = 1 . . . , i
s
Ns
for the cluster according to the
joint conditional posterior distribution.
9. end of s loop
10. end of r loop
peptide sequence. The peptide elution profile was modeled by an exponentially mod-
ified Gaussian distribution, which captures different distortions of elution peaks by
considering tailing and fronting effects [62]. Each output data set consists of 100 MS
spectra with mass resolution 15,000.
BPDA2d, BPDA and msInspect (the latest Build 613) were applied to the same
data sets to give detection results. We mainly focus on the performance comparison
between BPDA2d and its precursor BPDA, which was shown to outperform popular
algorithms such as OpenMS (Version 1.6.0), Decon2LS and VIPER in [39]. We also
include msInspect in the comparison since it is widely used and has been reported
to outperform other algorithms [63] such as MZmine. To apply BPDA, we followed
the procedure introduced in the original paper [39]: Peptide elution peaks were first
detected along the RT dimension, and elution peaks with similar RT were grouped.
Each group contains a series of consecutive spectra, which were then averaged to form
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a mean spectrum. Each mean spectrum was analyzed by BPDA, and finally an overall
feature list was produced. To apply msInspect, we first wrote each simulated data set
into a text file with three columns specified by RT, m/z, and intensity. Next, the text
file was converted to mzXML and then msInspect was applied to give detection results
including detected features and their qualities. The input parameters of msInspect
were set to enable the inclusion of as many reasonable features as possible (“minpeaks”
and “maxkl” were set to 2 and 10, respectively).
When comparing BPDA2d to its precursor BPDA, we found that the former
had several advantages over the latter as detailed below. (I) For each experiment
conducted, the total number of candidates considered in BPDA2d was greatly reduced
compared to BPDA (reduced by 43% on average). This is expected since BPDA2d
imposes additional constraints on candidates’ elution peaks and can preclude non-
reproducible noise peaks from the candidate list. To clarify, BPDA2d searches for
candidates which can be repetitively observed across retention time — i.e. candidates
whose elution peaks can be clearly identified. Thus, a major fraction of noise peaks
(e.g. shot noise) which are not reproducible in time is removed. In contrast, BPDA is
a 1D algorithm which works along the m/z dimension and processes one mean scan at
a time. The mean scan is produced by taking the average of a few consecutive spectra.
Thus, although noise in the form of random intensity fluctuation can be canceled out
to some degree, non-reproducible noise peaks are still likely to be included in the
resulting mean scan and therefore in the candidate list. Also, BPDA is likely to split
long elution peaks into multiple mean scans and thus generate multiple candidates for
a single true peptide. In summary, BPDA2d can compile a more reliable candidate
list, which may help to reduce the number of detected false positives (FPs), and can
allocate limited computational resources to candidates more likely to be true positives
(TPs).
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(II) BPDA2d reported significantly fewer FPs with existence probability larger
than 0.9 than BPDA (reduced by 47% on average) and detected more TPs than the
latter (increased by 6% on average). This improvement of BPDA2d is achieved by
taking into account peptide elution peaks in addition to isotopic distribution and
charge station distribution. BPDA2d tries to use all available observations from
possible positions on the m/z-RT plane to infer the overall signal of each peptide
candidate. By utilizing more information, detected signals become more reliable and
the evidence of candidates’ existence or non-existence becomes stronger, resulting in
better detection results in terms of more TPs and less FPs.
When comparing BPDA2d to msInspect, we found that on average the TPs
detected by BPDA2d increased by 16% than the latter while the FPs reduced by 40%
(quality thresholds were set to existence probability larger than 0.9 and KL less than
1, for the two algorithms respectively).
To give a complete picture of the detection results, the classic Precision-Recall
(PR) curve was adopted to evaluate the performance of various algorithms since
the ground truth of the data is known. To obtain the PR curve, first a series of
detection levels was selected, which range from the lower bound to the upper bound
of feature quality scores (i.e. existence probability for BPDA and BPDA2d; KL score
for msInspect). Features with quality score better than a given detection level were
said to be detected at this specific detection level. A detected feature was claimed to
be a true positive if it had the correct monoisotopic mass (e.g. within 10 ppm of the
true mass), the correct RT (with a 6-scan tolerance), and the true RT is within the
boundaries of the feature’s elution peak ; otherwise the detected feature was called a
false positive. Then, the True Positive Rate (TPR, i.e. recall) and precision (Prec)





. The averaged PR curve for one abundance level was
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then obtained (each point on the curve was a pair of averaged precision and TPR
at one detection level for all repetitions). We found that the Precision-Recall results
were largely influenced by the size of the mass window used for matching detected
features with the list of true peptides. Thus we plotted the Precision-Recall curves
for various mass windows as shown in Fig. 4.
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Fig. 4. Precession-Recall results for synthetic LC-MS data sets with different abun-
dance levels (SNRs). Each panel shows the results obtained at a different mass
window size as suggested by the title. Color codes for different abundance lev-
els. Each method is represented by a unique line type. BPDA2d renders the
best precision and sensitivity (i.e., recall) among all the methods compared for
all abundance level in the first two mass window cases. In the last case, the
performance between BPDA2D and msInspect has a very small difference.
In the PR space, the upper right corner ( with a coordinate of [1,1]) represents
100% sensitivity (no false negatives) and 100% precision (no false positives). The
closer the PR curve to the upper right corner, the better the algorithm. In this
sense, BPDA2d is generally the best among all methods at all abundance levels.
BPDA2d’s performance is the least affected by the deterioration of SNRs among the
three algorithms. Thus BPDA2d provides the most robust performance for lower
abundance peptides.
Another advantage of BPDA2d is that it has much higher reported mass accu-
racy. Fig. 5 compares mass accuracies of all three algorithms. It can be seen that
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the mass accuracy reported by BPDA2d is significantly higher than the other two
algorithms. Given different mass accuracies, there is not a fair way for performance
evaluation. Thus we provided performance evaluation in three cases when different
mass window sizes were used. It can be seen that the mass window size does not af-
fect the performance of BPDA2D significantly after 10 ppm because of its high mass
accuracy. On the other hand, msInspect deteriorates quickly as we narrow the mass
window from 20ppm to 10ppm due to its low mass accuracy. BPDA2D outperforms
msInspect at higher mass accuracies of 10ppm and 5ppm. In the case of 20ppm, given
the simple composition of the simulated data, the performance between BPDA2D and
msInspect is similar. It shall be noted that with different mass accuracies by different
algorithms, sample composition will strongly affect the reported PR curve — If the
sample is more complex, with more peptides of similar weights, algorithm with lower
mass accuracy like msInspect will further deteriorate in performance.
b. Synthetic LC-MS data set with 8 pairs of overlapping peptides
As noted, overlapping peptide peaks can complicate mass spectra and make the de-
tection problem much harder. Hence, it is important to investigate algorithm per-
formance in the presence of overlapping peptides. A synthetic 16-peptide-mix was
generated by 8 pairs of overlapping tryptic digested human peptides. The data set
contains 1000 LC-MS spectra with mass resolution 15,000. The intensity ratio of each
pair (light/heavy) ranges from 0.25 to 3, and peptide charge states range from 1 to
4. More details on these peptides and the detection results of different algorithms are
summarized in Table V.
For the first 4 pairs, the challenges are mainly to detect and split overlapping
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Fig. 5. Mass deviation of reported features that can be matched to the ground truth
peptide list using a 20 ppm mass window (along with other criteria imposed on
the retention time as described in the text). Each panel represents a detection
algorithm as suggested by the subtitle. The plot was obtained by normalizing
the mass deviation histogram by the total number of true peptides. It can
be seen that BPDA2d has a much higher mass accuracy than the other two
algorithms: the density around 0 ppm given by BPDA2d increased by around
4 times compared to BPDA and msInspect; and the SD of mass deviation is
3.7, 4.6, and 6.9 ppm for BPDA2d, BPDA and msInspect, respectively.
elution peaks of the two peptides in each pair with similar weights and close RT. For
instance, the elution profiles and observed signals of the two peptides in the 1st pair
are shown in Fig. 6. We observe that the two peptides have significant overlapping
signal regions, which makes the detection problem tough. MsInspect experienced
difficulty in identifying this pair. In fact, it failed to split the overlapping elution
peaks and treated the two peptides as a single one. As a result, the intensity of the
reported peptide (the 2nd one) equals the total intensity of the two. For BPDA,
although it could report both peptides correctly, the intensity results were inaccurate
(the intensity ratio turned out to be greater than 1 while the true ratio was 0.67).
BPDA detected the second peptide correctly from 106s to 128s (approximately from
the beginning to the maximum of the second peptide’s elution profile, see Fig. 6(a)),
while the rest of the signal peaks which appeared after 128s were shadowed by the
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Fig. 6. Overlapping signals of the first pair in 16-mix. a) Overlapping LC profiles of
the two peptides. (b) Signal peaks of the two peptides at charge state 1 in a
3D view. SNR at this region is quite low, and significant peak overlapping can
be observed.
1st peptide, whose signal was stronger. Therefore, in this region BPDA failed to
include the 2nd peptide in its candidate list and tried to use the 1st peptide alone to
explain the observed signal. The second peptide’s corresponding intensity was thus
wrongly attributed to the first one, thereby leading to inaccurate intensity results.
In contrast to msInspect and BPDA, BPDA2d correctly split the elution peaks of
the two peptides by capturing the tiny mass difference of the two and by detecting
intensity dips in the observed overlapping peaks.
For the last 4 pairs, the weights of two peptides in each pair differ approximately
by a multiple of the neutron weight. As a result, their isotopic peaks overlap at
different isotope numbers and the overall isotope pattern deviates from each individ-
ual’s. Thus, it is more challenging to utilize individual isotope pattern to discern the
overlapping pair. As a vivid example, the elution profiles and the observed signals
of peptides in the sixth pair are shown in Fig. 7. It is observed that the SNR at
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Fig. 7. Overlapping signals of the sixth pair in 16-mix. (a) Overlapping LC profiles.
(b) Signal peaks of the two peptides at charge state 3 in a 3D view. This
region has a high SNR, where peaks of the 2nd peptide almost get completely
shadowed by all but the first isotope peak of the 1st peptide. (c) MS scan
sampled at 78s showing signals of the same pair. The observed overall signal
pattern deviates from (d) the theoretic isotope patterns of the two peptides.
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Table V. Results of the data set with 8 pairs of overlapping peptides
Pair No.
True peptide info BPDA2d BPDA msInspect
Sequence Mass(Da) RT(s) CS Intn CS Intn CS Intn CS Intn
1
DYSYER 831.34 141 1-2 .0004 1-2 .0003 1-2 .0008 NA
DENGELR 831.37 127 1-2 .0006 1-2 .0006 1-2 .0005 1-2 .001
2
VVFMSLCK 925.48 414 1-2 .0046 1-2 .0033 1-2 .0043 1-2 .0050
LLLPCLVR 925.58 456 1-2 .0054 1-2 .0044 1-2 .0056 1-2 .0068
3
MTPELMIK 961.50 323 1-3 .0001 1-3 .0001 1-3 .0001 1-2 .0001
IAVMLMER 961.51 340 1-3 .0002 1-3 .0002 1-3 .0003 1-3 .0003
4
ACCLLCGCPK 1009.42 302 1-3 .0011 1-3 .0008 1-3 .0023 1-3 .0024
MLCAGIMSGK 1009.48 314 1-3 .0008 1-3 .0009 1-3 .0014 1-3 .0020
5
AYDPDYER 1027.42 174 1-3 .0077 1-3 .0078 1-3 .0081 NA
EEPSGDGELP 1028.43 194 1-3 .0307 1-3 .0344 1-3 .0418 1-3 .0382
6
NGNEEGEER 1032.41 75 1-3 .4612 1-3 .5110 1-3 .7140 1-3 .7284
TEGEEDAQR 1033.43 79 1-3 .1537 1-3 .1065 NA NA
7
MLANLVMHK 1055.56 312 1-3 .0019 1-3 .0018 1-3 .0017 1-3 .0023
LTLDLMKPK 1057.62 321 1-3 .0009 1-3 .0010 1-3 .0008 NA
8
LLPPLLQIVCK 1235.77 561 1-4 .1768 1-4 .1755 1-4 .1405 1-4 .1193
LMLFMLAMNR 1238.63 577 1-4 .1537 1-4 .1516 1-4 .0779 1-4 .0943
CS and Intn denote detectable charge states and normalized intensity, respectively.
corresponding regions was quite high and peaks of the second peptide in this pair
almost got completely shadowed under all but the first isotope peak of the first pep-
tide (Fig. 7(a),(b)). Hence, the overall signal pattern (Fig. 7(c)) deviates from each
individual’s isotope pattern (see Fig. 7(d)). MsInspect was not able to detect this
deviation: The calculated KL distance between the overlapping peak cluster and the
first peptide’s theoretical isotope pattern was surprisingly small (around 0.027), sug-
gesting a ’good’ match by its own criterion (a smaller KL score suggests a better
match). MsInspect thus stopped there and assigned all overlapping signals to the
first peptide, failing to consider the second peptide. This failure was not caused by
chance. In fact, for the last 4 pairs, msInspect could correctly detect only one pair
of peptides (the one with the least overlap) and missed one peptide in each of the
other 3 pairs. This illustrates the inefficiency of template matching algorithms such
as msInspect in dealing with overlapping isotope patterns as compared to BPDA2d
and BPDA. Indeed, one should be wary of taking KL distance, or other distance
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measures adopted by template matching algorithms, as a reliable measurement of the
isotope pattern deviation. BPDA proposed a candidate corresponding to the second
peptide; however, the candidate’s existence probability was inferred to be 0, thereby
rendering it undetectable. This was caused by the penalty term adopted in BPDA
that penalizes model complexity. More specifically, the additional inclusion of the
second peptide could reduce the MSE between the observed and inferred peaks to a
small extent, but this reduction in MSE could not beat the increase of model com-
plexity. Therefore, BPDA inferred the second peptide to be non-existent. Although
BPDA2d utilizes a similar penalty strategy, the penalty term did not cause exclusion
of the second peptide because BPDA2d used more observations from the m/z-RT
plane than BPDA and the improvement in fitting the observed signal by inclusion of
the second peptide was significant, thereby offsetting the penalty.
In summary, BPDA2d correctly detected all 46 charge states of the 16 peptides
(along with 16 FPs), while BPDA and msInspect correctly detected 43 and 34 charge
states, along with 57 and 4 FPs, respectively. All detected TPs of BPDA2d and
BPDA had existence probability equaling to 1. For msInspect, the KL scores of TPs
were less than 0.76. The box plots of mass and intensity deviation results given by the
three algorithms are shown in Fig. 8. We observe that among the three algorithms, on
average BPDA2d gave the most accurate abundance results and msInspect’s results
were the least accurate. BPDA had the best mass accuracy evaluated by the median
mass deviation, but it rendered a few outliers and a larger variance compared to
BPDA2d. Overall, msInspect produced the least accurate mass results. The synthetic










































Fig. 8. Box plots of (a) absolute mass deviation and (b) normalized intensity deviation
of BPDA2d, BPDA and msInspect for the 16-mix data set
2. Results for real data
a. Data preparation
A QTOF LC-MS/MS data set was downloaded from the repository of the Seattle Pro-
teome Center that is provided as a standard for testing algorithms. The data set was
collected on a Waters/Micromass (Milford, MA) Q-TOF Ultima with Agilent 1100
series autosampler, Agilent 1100 series nanopump flowing at 200 nL/min and electro-
spray ionization. Approximately 200 fmol of total protein was injected on-column.
The data set contains over 3500 MS1 spectra (m/z ranges from 250 to 1400 with
FWHH around 0.15 Da.) and 775 MS2 spectra generated by peptides from 18 tryptic
digested proteins (obtained from Bovine, Rabbit, Horse, etc.). More details can be
found in [64]. MS1 level peptide detection was performed using BPDA2d, BPDA, and
msInspect (the latest Build 613). We tried to optimize input parameters for msIn-
spect: “minpeaks” was set to 2 and “maxkl” was set to 10, enabling the inclusion
of as many reasonable features as possible. The “walksmooth” option was selected
as it was recommended for QTOF data and improved the performance. For BPDA,
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post-processing was applied to combine features that were split over consecutive mean
spectra.
b. Comparative results
Direct comparison of results across different methods is meaningless unless ground
truth of the data is known, but owing to contaminants and issue of peptide detectabil-
ity, the true data composition is hard to know. As a workaround, SEQUEST and
PeptideProphet were applied to analyze all the acquired MS2 spectra, rendering 234
unique peptide identifications associated with a high probability score (i.e. Peptide-
Prophet score greater than 0.9) and could somehow reveal a portion of the truly
existing peptides in the sample. We thus compared the detection results given by
aforementioned MS1-based methods to the MS2 identifications. We say a MS1 fea-
ture is matched to a MS2 feature if the RT of the MS2 feature is within the retention
peak of the MS1 feature and the mass deviation is within 40 ppm. The size of the
mass window is chosen to include as many good matches as possible. It is larger
than that used for synthetic data since here the ground truth peptide weights are
unknown, and mass errors are associated with MS2 identifications as well as MS1
features. MS1 identifications were first filtered based on mass and RT. Only features
with mass 1000-3710 Da. and RT in the range of 840 to 2030 scan were considered
since all MS2 identifications were from these ranges. Remaining features were then
selected based on the reported quality score. Because schemes used for calculating
feature quality score vary across different algorithms, to ensure a fair and meaningful
comparison, quality cutoff thresholds for various algorithms were carefully chosen as
detailed below so that they corresponded to the same significance level.
• For BPDA2d and BPDA, existence probabilities are employed to measure fea-
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ture quality. The cutoff thresholds of existence probability were calculated based
on its null distribution, i.e. the distribution of existence probability of those
candidates that are non-existing in the sample. We identify these peptides as
those highly correlated ( i.e. can be grouped into the same cluster as described
in Method section) with one of the candidates that can be matched to the MS2
identification list. Although the ground truth is unknown, the latter candidates
are likely to be TPs as they are confirmed by the MS2 identifications with high
reliability, while the former are false identifications co-existing with the latter.
These co-existing candidates should be assigned with a low existence probabil-
ity. Given a significance level α, the corresponding threshold γ of the existence
probability p can be calculated based on the right-tail probability of the null
distribution: {γ|Prob(p ≥ γ) = α}.
• MsInspect uses KL score to measure feature quality. Cutoff KL thresholds were
selected based on KL null distribution, i.e. the distribution of KL scores calcu-
lated between random noise and authentic isotopic distributions, as described
in [65]. If KL score can faithfully reflect the deviation between random noise
and real isotopic patterns, then the KL null distribution should skew to the
right or have a small left-tail probability. On the other hand, given a signifi-
cance level α, the corresponding KL threshold τ could be calculated based on
the left-tail probability: {τ |Prob(KL ≤ τ) = α}.
From Fig. 9(a), it can be seen that BPDA2d detected many more features from
the MS2 list than BPDA and msInspect at each significance level compared. Im-
provements are from 32% to 18%, and 64% to 19% compared to BPDA and msIn-
spect, respectively, when significance level increases from 0.01 to 0.1, indicating a
3-6 fold increase in peptide coverage and quantification. In addition, all three MS1-
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based algorithms detected significantly more features than that covered by the 234
MS2 identifications (see Fig. 9(b)), illustrating the under-sampling problem of MS2
and highlighting the benefits of employing MS1-based peptide detection algorithms
to improve protein coverage rate. Performances of various algorithms were further
investigated at a 0.05 significance level. The histogram of normalized intensity of
MS2-level identifications detected by BPDA2d but not by msInspect is plotted in
Fig. 9(c). The majority of identifications detected only by BPDA2d concentrate at
the low intensity region (i.e. the area with normalized intensity less than 0.1), illus-
trating that BPDA2d can better identify low abundance peptides than msInspect.
In addition, extra identifications yielded by BPDA2d did not cause degradation in
mass accuracy (Fig. 9(d)). Moreover, BPDA2d slightly beat the other two methods
in terms that the mean mass deviation is reduced by around 2%.
The average computational time of BPDA2d, BPDA and msInspect for testing
data sets are 3.5 hr, 1 hr and 2.2 min, respectively. BPDA2d is expected to be
more time-consuming since it looks for the optimal solution iteratively through Gibbs
sampling on the whole spectra, while greedy template-matching based algorithms
work on one local region at a time and calculate the fitting score, which typically
does not require much computation. But we point out that the BPDA2D algorithm
is fully parallelizable, and the authors are in fact working on a parallel version of the
software that will be much faster.
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Fig. 9. Detection results of the QTOF LC-MS/MS data set. BPDA2d, BPDA and
msInspect detected (a) number of features that can be matched to MS2 iden-
tifications at various significance levels and (b) total number of features. At
significance level 0.05, the following two panels are obtained: (c) Histogram of
normalized intensity of features detected by BPDA2d but not msInspect. Most
of the features are from the low intensity region. (d) Box plots of absolute mass
deviation of different algorithms.
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CHAPTER IV
MODELING AND SYSTEMATIC ANALYSIS OF THE
LC-MS PROTEOMICS PIPELINE
In this chapter, we model and evaluate the LC-MS data analysis pipeline from a
systems point of view, with the goal of aiding experimental design, optimizing the
workflow, predicting experiment results, and identifying key factors and bottlenecks
that affect biomarker discovery results.
A. Background
1. Motivation
The MS analysis pipeline consists of many steps, including sample preparation, pro-
tein digestion, ionization, peptide detection, protein quantification, and so on. The
pipeline can be viewed as a noisy channel, where each processing step introduces some
loss or distortion to the underlying signal and the end results are affected by the com-
bined effects of all upstream steps. While individual components of the MS pipeline
have been studied at length, little work has been done to integrate the various mod-
ules, evaluate them in a systematic way, and focus on the impact of the various steps
on the end results of differential analysis and sample classification. In real experi-
ments, it is not easy to decouple the compound parameter effects and determine the
marginal influence of various modules on the end results, due to variations and the
complicated nature of the workflow. However, by employing a model-based approach,
we may better understand the characteristics of the MS data, the contributions of
the individual modules, and the performance of the full pipeline.
A key goal of MS-based proteomics is to discover protein biomarkers, which
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can be used to improve diagnosis, guide targeted therapy, and monitor therapeutic
response across a wide range of disease [6]. But to date, the rate of discovery of
successful biomarkers is still unsatisfactory. Through the proposed model-based ap-
proach and by means of simulation using ground-truthed synthetic data, the problem
of biomarker discovery can be studied and evaluated.
2. Results
In this work, we propose to model the Liquid Chromatography (LC) coupled MS
system by identifying critical factors that influence system performance. Different
modules are identified and integrated into the framework (see Fig. 10). The input of
the pipeline can be any standard FASTA file containing proteins of interest. Here, we
focus on analyzing protein drug targets downloaded from DrugBank [66], since LC-MS
is an essential technology used to monitor these target proteins for drug development.
We would like to point out that we are not trying to develop a detailed physical model
for mass spectrometry as is, for instance, attempted in [49], which models the mass
spectra generated by MALDI-TOF instruments. Rather, our purpose is to simulate
the data flow realistically, but without descending into the physical parameters of the
instrument itself. In addition, we do not focus only on MS data modeling, as done
in [19], but we also address subsequent processes, including low level data analysis (e.g.
peptide identification and quantification), and high level analysis (e.g. differential
analysis and sample classification).
3. Application of the proposed model
The proposed LC-MS proteomic pipeline model can be used to determine the work-
ing range of important parameters and may shed light on experimental design. Also,
if knowledge of sample complexity, instrument configuration, system variation and
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Protein FASTA file 
 
Sample preparation 
• In silico protein digestion  
• Retention time prediction 
 
LC-MS experimental factors 
• LC condition 
• Ionization efficiency 
• Experimental variation and noise 
• Measurement error 
Feature extraction 
• MS1-based peptide detection to 
obtain peptide mass, intensity, etc. 
• MS2-based database searching to 
obtain peptide/protein IDs 
Quantification 
• Applying quality filter 
• Peptide to protein 
abundance roll up 
 
Statistical analysis 
• Differential expression analysis 
• Feature selection, classification and validation 
Fig. 10. The proposed MS-based proteomics pipeline.
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detection accuracy is known beforehand, then by tuning corresponding parameters to
their estimated values, the pipeline can be used to predict results on protein identifi-
cation rates, protein differential analysis, quantification accuracies and classification
performance. These results can be used to assess the efficacy of biomarker discovery
in MS data.
B. Methods
1. Protein mixture model
In a typical label-free MS experiment, two sample classes (e.g. control vs. treatment)
are considered. Assume each class has M samples and all samples share up to Npro
possible protein species of a given proteome. Protein concentration in the pooled con-
trol sample is modeled by a Gamma distribution in accordance with the observations
in [67]:
ηl ∼ Gamma(t, θ) , l = 1, 2, . . . , Npro , (4.1)
where t = 2 and θ = 1000 are the shape and scale parameters. The concentration has
a dynamic range of approximately 4 orders of magnitude representing typical real-
world scenarios. For the pooled treatment sample, expression levels of some proteins




al, if protein l is over-expressed
1
al
, if protein l is under-expressed
1, otherwise
(4.2)
where the fold change parameter, al > 1, is sampled from a uniform distribution, as
specified in the Results section.
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Sample variation of each protein is modeled by a Gaussian distribution [68],
with means ηl and ηl fl in the control and treatment sample classes, respectively.
Considering the fact that protein expression levels are often correlated, the following
multivariate Gaussian (MVG) distribution is appropriate to model the interactions





[η1, η2, . . . , ηNpro ],Σ
)
, j ∈ class 0
MVG
(
[η1f1, η2f2, . . . , ηNprofNpro ],Σ
)
, j ∈ class 1
(4.3)
where the covariance matrix Σ has a block-diagonal structure — proteins within
the same block (e.g. proteins belonging to the same pathway) are correlated with
correlation coefficient ρ and proteins of different blocks are uncorrelated [69]:
Σ = [σ2lj]Npro×Npro ,
σ2lj = σllσjjrlj ,
(4.4)
where σll is proportional to the control protein mean ηl by a constant factor φl (i.e.,
the coefficient of variation), and the correlation coefficient matrix is
R = [rlj]Npro×Npro =

Rρ 0 · · · 0





0 0 · · · Rρ

,
where Rρ is a D×D matrix with 1 on the diagonal and ρ elsewhere. The correlation ρ
and block size D are tunable parameters, with values specified in the Results section.
2. Peptide mixture model
Before being analyzed by the MS instrument, proteins are usually digested into pep-
tides. In the proposed simulation pipeline, in-silico tryptic digestion is performed,
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and retention time of peptide products is predicted using the PNNL Protein Digestion
Simulator (http://omics.pnl.gov/software/ProteinDigestionSimulator.php). Dif-
ferent protein species may share the same peptide sequence. Thus, the molar concen-




cprokj , i = 1, 2, . . . , Npep, j = 1, 2, . . . , 2M , (4.5)
where the set Ωi comprises all proteins sharing the peptide species i, and Npep is the
number of peptide species. The concentration cpepij is represented by ion abundance
in MS data. Thus, the expected abundance readout µij of peptide species i in sample
j can be modeled as
µij = c
pep
ij ei κ, (4.6)
where ei is a peptide efficiency factor similar to the one used in [70], and κ is the
MS instrument response factor converting the original analyte concentration to the
output ion current signal. The parameter ei is affected by many factors: first, var-
ious peptides differ in hydrophobicity, which mainly determines their efficiencies in
passing through the liquid chromatography column. Then, upon entering the ioniza-
tion chamber, peptides demonstrate great disparities in ionization efficiency, which
is affected by sample complexity, peptide concentration and characteristics such as
polarity of side chains, molecular bulkiness, and so on [71]. In addition, some amino
acids at the N-terminal end of peptides have destabilizing effects that can reduce the
efficiency factor. Although there are methods attempting to predict ei [70], they often
neglect the fact that peptide efficiency and expected peptide ion abundance depend
not only on the underlying peptide, but also on the combinational effects of other
peptides present (e.g., LC elution competition, ion competition and suppression). In
reality, it is unfeasible to predict ei for all possible peptide combinations. Thus, we
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model ei from a uniform distribution and evaluate a wide range of interval bounds
in simulations — we are not really interested in the precise value of ei, but rather
we aim to examine how the dispersion of ei affects subsequent analysis. As for the
parameter κ, it can be estimated through calibration and is related to the efficiency
by which molecules are converted into gas-phase ions, the efficiency by which ions are
transferred through various stages of the mass spectrometer, and how well experiment
conditions are optimized. For a typical MS instrument, its response is linear for three
to five orders of magnitude [71]. At high analyte concentration, instrument response
plateaus because of detector saturation, restricted amount of excess charge, or limited
space for ionization, as depicted in Fig. 11. To account for instrument saturation, an












Fig. 11. The MS calibration curve which displays the MS ion signal as a function of
analyte concentration in solution. The slope of the linear portion of the curve
is the instrument response factor (i.e. instrument sensitivity). The curve
departs from linear at high analyte concentration. A wider linear dynamic
range is desired for quantitative analysis.
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3. Peptide detection and identification
a. Peptide abundance
The actual abundance vij of peptide species i in sample j is modeled as the expected
abundance plus Gaussian noise:
vij = µij + ij , (4.7)
where
ij ∼ Gaussian(0, αµ2ij + βµij) , i = 1, 2, . . . , Npep , j = 1, 2, . . . , 2M . (4.8)
The sources of noise include variation in experimental conditions, instrument variance,
thermal noise and measurement error. It is reported that the noise variance follows a
quadratic dependence on the expected abundance [72], which is reflected by Eq. 4.8.
The two parameters in the noise model, α and β, determine the noise severity. Their
value can be estimated using replication analysis, as explained in [72].
In electrospray ionization, peptides can be multiply charged. But we do not
model the charge distribution, considering the following facts: (1) Peptide charge
distribution and the maximum charge states are complicated by many factors such
as sample composition, analyte concentration and peptide conformation [73,74]. The
distribution is hard to predict and has not been well characterized. (2) In order to
get the abundance of a peptide, and further, its parent protein, the abundance of
peptide charge variants will eventually be summed up. We omit the intermediate
process since in reality many factors involved are not well understood.
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b. Peptide detection
Peptide detection from mass spectra is not an easy task — the observed peptide
signals are corrupted by noise and may also be affected by signals of other peptides,
and thus may deviate significantly from the expected pattern. The performance of
a peptide detection algorithm on a specific MS instrument and the underlying SNR
ultimately affect the number of detected true positives, i.e., the true positive rate
(TPR), as shown in [28, 39, 40, 75]. The SNR is defined as the ratio of signal power
to noise power, i.e., SNR , E[v]2/Var(v) = 1/(α + β
µ
), see Eqs. 4.7–4.8. It can
be seen that SNR increases as signal strength µ increases. The relationship between
TPR and SNR can be approximated by a polynomial function, for algorithms such
as those in [39,40,75]:
TPR = k × SNRp + b , (4.9)
where b represents the worst TPR when the SNR approaches zero.
Besides SNR, signal interference and mass resolving power may also have con-
siderable impact on TPR [19,40]. Over the years, much effort has been made towards
enhancing instrument resolution, leading to improved mass accuracy, better separated
MS peaks, and less convoluted peptide signals. But for complex samples, substantial
overlapping of peptide signals is still frequently encountered, due to peptide isoforms
or co-elution. It has been reported that if two peptides have overlapping signal regions,
some detection algorithms may fail to report one of them even when the underlying
SNRs are high, while other algorithms are shown to be superior in the detection of
overlapping peptides [39]. To account for signal interference, we modify Eq. 4.9 by
introducing an overlapping factor oij, so that the TPR of peptide species i in sample
j becomes
TPRij = (k × SNRpij + b)× oij , oij ≤ 1 . (4.10)
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For algorithms such as NITPICK [28], BPDA [39] and BPDA2d [40], which are effec-
tive in detecting overlapping peptides, the overlapping factor oij can be approximated
by 1, whereas for algorithms that are ineffective in detecting convoluted peptides, oij
is assumed to be inversely proportional to the number of overlapping peptides, which
is a function of the sample composition and the mass resolution. In our simulation,
two peptide species i1 and i2 are said to overlap if their mass and retention time (RT)









< 0.005 . (4.11)
c. Peptide identification
The output of the MS1-based peptide detection algorithm is a list of detected pep-
tides annotated by monoisotopic mass, retention time, abundance, and so on. To
obtain peptide sequence information, i.e. peptide identification, which can be used to
infer the parent protein from which the peptide was digested, database searching is
required. To do so, the acquired MS/MS (MS2) spectra are searched against a pro-
tein database containing theoretical MS2 spectra generated from in-silico digested
peptide sequences by popular software such as SEQUEST [76] and Mascot [20].
Several machine learning methods have been proposed to predict the probabil-
ity (i.e., identifiability) of a peptide being identified through MS2 database search-
ing [68, 77]. These methods try to extract the common trends residing in peptide
identifiability that can be explained by peptide sequence-specific properties. Their
successful application may suggest that the peptide sequence largely affects the chance
of a peptide getting selected for MS2 analysis, whether the peptide can be sufficiently
fragmented, and the quality of its fragmentation spectra. In our simulation, the iden-
tifiability pi of the true peptide species i is predicted by the APEX software [68],
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trained on the human serum proteome [78], and whether peptide species i in sample
j is identified or not through database searching is determined by the outcome of a
Bernoulli trial with success rate pi.
d. Linking of detection and identification results
For both MS1-based and MS2-based algorithms, sources of error exist that give rise
to false positives (FPs). For the former, error sources include shot noise, abundance
measurement error, signal interference, and so on. For the latter, co-eluting precursor
ions, spectra matching ambiguity, or post-translational modifications may all lead to
false identifications. By confronting the results of the two orthogonal algorithms (i.e.,
a feature is treated as a true positive if it is reported by both algorithms), dubious
features reported by either algorithm can be filtered out.
4. High-level analysis
a. Peptide to protein abundance roll-up
As demonstrated in the previous sections, each step of the MS analysis pipeline intro-
duces a degree of loss or distortion to the underlying true signal. Thus, “decoding”
protein abundance from observed peptide abundance corrupted by noise is nontrivial.
To reduce noise, three levels of filtering are applied: (1) only unique peptides that
exist only in one protein of the analyzed proteome are kept; (2) peptides with large
missing value rates (larger than 0.7) are filtered out, since low reproducibility may
be a red flag for false identifications; (3) among the remaining peptides, those having
sufficiently high correlations (larger than 0.6) with other peptides digested from the
same protein are retained. The estimated abundance of protein l in sample j is then
obtained by averaging the abundances of its children peptides that pass the previous
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filters; if less than two peptides pass the filters, the estimated protein abundance is set
to zero. The estimated protein concentration is calculated by dividing the estimated
protein abundance by the instrument response factor κ.
Quantification accuracy can be assessed by the commonly adopted mean quan-






|cprotlj − cˆprotlj |/cprotlj
2MNpro
, (4.12)
where cprotlj and cˆ
prot
lj are the original and estimated concentrations of protein l in
sample j, respectively.
b. Differential expression analysis
Differential expression analysis is performed via a two-sample t-test with equal sample
size and variance. The t statistic (or t score) is calculated as below:
tl ,
|m1l −m0l |√





where the superscripts identify the two classes, and ml and V arl represent the es-
timated class mean and variance of the abundance of protein l, respectively. The
standard 0.05 significance level is used to detect differentially expressed markers.
c. Feature selection and classification
In the simulation, t-test feature selection is first performed to reduce the data dimen-
sion, by selecting the top 20 differentially expressed features. Then two classifiers,
namely K-nearest neighbor (KNN, K=3) and linear discriminant analysis (LDA) are
trained using the observed protein expression data. Classification performance is
validated by independent ground-truth (testing) data sets (each with 1000 samples,
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generated from the same data model), and the classification error is recorded. In
addition, the KNN and LDA classification error on the original protein data (before
entering the MS analysis pipeline) is obtained using a similar approach. The latter
may serve as a benchmark to gauge how much loss in classification performance the
analysis pipeline has introduced.
C. Results
To illustrate the application of the proposed pipeline model, a FASTA file containing
around 4000 drug targets (human proteins) was compiled from DrugBank [66], which
serves as the underlying proteome to be studied. In each run, 500 background proteins
along with 20 marker proteins are randomly selected from the proteome to serve as
the input of the pipeline. For each experimental setting studied, the simulation is
repeated 50 times. We are interested in the effects of various factors on quantification,
differential analysis, and classification. The study should be carefully designed to
minimize parameter confounding effects. Thus, while examining the effects of one
parameter, we either fix the values of other parameters, or try to eliminate their
effects. Parameter configurations are given in Table VI, unless otherwise mentioned.
1. Sample characteristics
a. Effect of peptide efficiency factor
Though the exact distribution of the peptide efficiency factor ei is unknown, we eval-
uate a wide range of values and try to find the common trend. It can be seen from
Fig. 12(a) that as the lower bound of ei increases, the quantification error decreases.
This is expected since more ions can be detected by the instrument and transmis-
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Table VI. Proteomics pipeline model summary
Parameters Default values
No. of classes 2
Sample size of each class M = 50
Proteome Homo sapiens
No. of marker proteins 20
No. of non-markers 500
Protein block size D = 2
Protein block correlation ρ = 0.6
Fold change al ∼ Unif(1.5, 2)
Instrument response κ = 5
Instrument saturation effect sat = Inf
Noise level α = 0.03, β = 3.6
Peptide efficiency factor ei ∼ Unif(0.1, 1)
Peptide detection algorithm b = 0, k = .0016, p = 2
No. of MS2 replicates 1
sion loss is reduced as efficiency increases. Fig. 12(b) suggests that the percentage
of observed differentially expressed proteins is positively correlated with ei: this may
be explained by the fact that as ei increases, fewer missing values occur at the pep-
tide level, and more proteins can be quantified in more samples, as can be seen in
Fig. 12(c), resulting in more markers being detected by the differential expression test.
Fig. 12(d) shows that the additional detected markers help to improve classification
accuracy by decreasing the classification error.
b. Effect of protein abundance
The distribution of in-solution protein abundance can affect various detection results
[79]. While high-abundance proteins are easily detectable, low-abundance proteins
are hard to detect since their signals are more likely to be buried in background
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Fig. 12. Various quantities plotted as a function of the lower bound of peptide effi-
ciency factor (the upper bound is fixed at 1). (a) Mean quantification error
as defined in Eq. 4.12. (b) Percentage of observed differentially expressed
marker proteins at a 0.05 significance level. (c) Missing value rates at the
protein and peptide levels. (d) Classification error rates given by LDA and
KNN classifiers, respectively.
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noise. Hence, improving detection of low-abundance proteins has become a central
issue in proteomic research.
To demonstrate the effect of protein abundance on the detection of low-abundance
marker proteins, we conduct an experiment where all markers are exclusively designed
to have low abundance, distributed in the lower 25% quantile of the Gamma distri-
bution; see Eq. 4.1. Fig. 13 depicts the corresponding plots to Fig. 12(b) and 12(d)
in the case of the low-abundance markers. It can be observed that the percentage of
detected differentially expressed markers and the classification results become worse
compared to the results in Fig. 12(b) and 12(d). On average, the number of detected
markers drops by 33.3% and the classification error increases by 42.4%. Similar trends
are observed under other parameter settings (data not shown).
These results indicate that it is essential to develop methods to enhance the
identification results of low abundance peptides which are often of more biological
interests. Relative to hardware, sample fractionation and protein depletion through
immunoaffinity-based approaches [80] can be helpful. Relative to software, there exist
algorithms shown to be efficient for the detection of low-abundance peptides, such as
BPDA2d [40].
c. Effect of sample size
Fig. 14 shows the effect of sample size. The range of values used is typical in proteomic
experiments. It is observed that as more samples become available, the differential
expression results and the classification accuracy improve notably. For instance, when
sample size increases from 30 to 110, the number of detected markers increases by
41% and the classification error decreases by 40%.
In Fig. 14(b), the classification error of the (unobserved) original protein sample,
before passing though the MS pipeline, is plotted side by side with that of the observed
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Fig. 13. Effect of peptide efficiency factor on (a) differential expression results, and
(b) classification errors for samples with reduced marker concentration. Re-
sults deteriorate compared to those using the default protein concentration
(Fig. 12(b) and 12(d)).
protein data, after analysis by the MS pipeline. The performance degradation caused
by various noise conditions throughout the pipeline is clearly visible.
2. Instrument characteristics
a. Effect of instrument response
The effect of instrument response factor κ is displayed in Fig. 15. The experimental
value of κ spans seven orders of magnitude. As κ first increases (from 0.1 to 100), true
signals get amplified and SNRs become better, resulting in fewer missing values and
false negatives at both peptide and protein levels (Fig. 15(a)), which in turn render
better quantification and differential expression results (Figs. 15(b) and 15(c)). But
when κ > 100, various performance indices level off. This illustrates that beyond a
certain point, merely boosting the instrument response factor cannot help produce
enhanced results. Rather, the performance bottleneck is determined by other factors
such as noise in the system and efficiency of peptide detection algorithms.
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Fig. 14. Effect of sample size M on (a) differential expression results, and (b) classi-
fication error rates. All results generally improve as M increases. In (b) the
classification error of the original protein sample (dashed lines) is plotted side
by side with that of the observed protein data (solid lines), illustrating the
substantial loss in accuracy introduced by the MS analysis pipeline.
b. Effect of saturation
In the previous experiment, the MS instrument is assumed to be working in the
linear range. But for complex samples, for which analyte concentrations span orders
of magnitude, saturation effects need to be taken into account (see Fig. 11). The
previous experiment is repeated with the same settings, except that the saturation
upper limit sat is changed from infinity to 104, corresponding to a 104 linear dynamic
range when κ = 1. Interestingly, the resulting plots shown in Fig. 16 are no longer
monotone as observed in Fig. 15. As the instrument response κ increases, the linear
dynamic range (LDR) actually shrinks given the saturation ceiling is fixed (LDR can
be approximated by sat/κ). Therefore, the percentage of peptides with saturated
ion signals increases, and fewer peptides can pass the correlation filter, adversely
affecting protein detection, quantification, and classification. To wit, when κ > 10,
the protein missing value rate shoots up, fewer markers get detected, and classification
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Fig. 15. Effect of instrument response factor κ on (a) missing value rates, (b) quantifi-
cation accuracy, (c) differential expression results, and (d) classification error
rates. As κ increases, all performance indices improve quickly and then level
off.
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performance and protein quantification results deteriorate.



















































































Fig. 16. Effect of instrument response κ in the presence of saturation on (a) missing
value rates, (b) quantification accuracy, (c) differential expression results, and
(d) classification error rates. As κ increases, all performance indices at first
improve and then deteriorate (except for the peptide missing value rate, which
levels off).
The compound effects of instrument sensitivity and saturation demonstrate that
the effectiveness of MS in quantitative analysis relies on achieving a wide linear dy-
namic range with a high saturation ceiling and a matching sensitivity. For example,
in electrospray ionization mass spectrometry, the linear range may be extended by
enhancing gas-phase analyte charging, facilitating droplet evaporation, or introducing
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ionization competitors [81].
c. Effect of noise
Noise in the MS analysis pipeline and the performance of peptide detection algorithms
affect the number of proteins that can be quantified. To study noise impact directly,
we eliminate the confounding effects of the peptide detection algorithm by assuming
perfect detection, with TPR ≡ 1 for SNR > 0 and TPR = 0 for SNR = 0. It
is observed in Fig. 17(a) that the peptide missing value rate stays relatively flat
except at the end points where the accumulated effects of increasing noise levels are
discernable: more of the true signal is obscured by noise and more peptides have
infinitesimal SNR, which prevent their detection. The increasing trend in missing
value rate at the protein level is more apparent: the fact that less proteins can be
quantified as the noise level increases is not only due to fewer detectable peptides,
but also because fewer peptides can pass the correlation filter for a protein to be
quantified. Figures 17(b), 17(c) and 17(d) elucidate the adverse effects of noise on
quantification accuracy, differential expression and classification results, respectively.
3. Peptide detection and experimental design characteristics
a. Effect of MS1 peptide detection algorithm
Given the same experimental settings, the performance of peptide detection algo-
rithms may significantly affect the number of detected true positives (TPs). Three
hypothetic detection algorithms with increasingly better performance are considered,
in terms of TPR vs. signal strength curves; see Fig. 18(a). It can be seen in Fig. 18(b-
e)) that the application of these detection algorithms leads to increasingly better re-
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Fig. 17. Effect of noise on (a) missing value rates, (b) quantification accuracy, (c)
differential expression results, and (d) classification error rates. The x-axis
represents α in the noise model given by Eqs. 4.7–4.8, while β is set to be
120α. The parameter values in the middle of the range (α = 0.04, β = 4.8)
were estimated by an LC-MS analysis of human serum samples
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sults in terms of missing value rate, quantification accuracy, detectable markers, and
classification performance.
b. Effect of overlapping peptides and mass resolving power
To quantitatively evaluate the performance of MS1-based peptide detection algo-
rithms under various mass resolutions and in the presence of overlapping peptides,
two categories of detection algorithms are compared: the first characterizes those
which can effectively detect convoluted peptides, such as NITPICK [28], BPDA [39]
and BPDA2d [40], which are modeled by an overlapping factor oij = 1 in Eq. 4.10,
and the second represents those that are sensitive to mass resolution and ineffective in
detecting overlapping peptides (e.g. algorithms based on greedy template-matching),
which are modeled by letting oij be inversely proportional to the number of overlap-
ping peptides with peptide i in sample j. For algorithms in the first category, robust
performance is expected for a range of mass resolutions (data not shown). In contrast,
for algorithms in the second category, various performance indices generally become
worse as mass resolving power declines, since more peptides cannot be resolved and
are lost in detection (see Fig. 19). Summing up, the superiority of the first category
over the second will be more evident for complex samples with more proteins and
co-eluting analytes analyzed by a MS instrument with limited mass resolution.
c. Effect of MS2 replication
In tandem MS analysis, the precursor ions selected for fragmentation have low re-
producibility across runs, and only a subset of peptides present in the sample can
be analyzed for each run; this problem is known variously as MS2 random sam-
pling and MS2 under-sampling [82]. Hence, though laborious and costly, replicate
MS2 measurements are frequently conducted for in-depth proteomic profiling or for
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Fig. 18. Effect of using three hypothetic detection algorithms with increasingly better
performance, quantified by the (a) TPR vs. signal strength curves. The
applications of the three algorithms lead to increasingly improved results in
terms of ((b) missing value rates, (c) quantification accuracy, (d) percentage
of detectable markers, and (e) classification error rates.
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Fig. 19. Performance of a typical peptide detection algorithm in the second category
described in the text under various mass resolutions and in the presence of
overlapping peptides. (a) Missing value rates, (b) quantification accuracy, (c)
differential expression results, and (d) classification errors.
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building an AMT database to facilitate quantitative and high-throughput proteome
measurements [83].
The effect of MS2 replication on various performance metrics is illustrated in
Fig. 20. It is observed that even with a few replicate assays (as low as two or three),
peptide and protein identification rates are boosted remarkably. As more replicates
are made available, the protein identification rate levels off faster than the peptide
rate, which was also observed in [78], indicating that newly identified peptides are
mostly associated with already identified proteins. This may be explained as a bias
towards relatively easily detectable proteins. Those proteins that are hard to detect
may be a result of degradation, a spare amount of children peptides, ineffective ion-
ization, and so on. Figs. 20(a) and 20(b) show that more proteins are detectable with
improved quantification accuracy as the number of replicates increase. Comparing
the use of three replicates against a single assay, Fig. 20(c) shows that the number
of detected differentially-expressed marker proteins nearly doubles, while Fig. 20(d)
indicates that the LDA classification error enjoys a 67% decrease.
4. Summary
The median value of each performance index across all previously studied cases with
default sample size 100 is given in Table VII. It can be seen that the protein quan-
tification rate exceeds the peptide identification rate. This may be explained by the
one-to-many map from protein to its digested peptides: a protein can be quantified if
more than one of its children peptides are identified and can pass the aforementioned
quality filter. In the proteome studied, on average, one protein can be digested
into around 20 peptides, and if we simply assume that each child peptide can be
identified with a probability 0.17 (the calculated average peptide identification rate),
independent of other peptides, and ignore the additional effects of the quality filter,
88

























































































Fig. 20. Effect of MS2 replication on (a) missing value rates, (b) quantification accu-
racy, (c) differential expression results, and (d) classification errors. It can
be seen that replicate analysis can significantly boost peptide and protein
identification rates, quantification and classification results even only a few
replicates are made available.
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then the protein quantification probability (an upper bound) can be approximated by
1− (1− 0.17)20− 20× 0.17× (1− 0.17)19 = 0.88. The typical percentage of detected
differentially-expressed protein markers is around 50% and the median value of the
LDA classification error on the observed protein data is 0.18, which is 17 times larger
than that of the original protein data — this exemplifies the signal corruption and
error propagation introduced by the MS analysis pipeline, as well as the intricacy of
biomarker discovery and their applications in disease diagnosis due to limited sample
size, signal interference, ubiquitous noise, measurement errors, and so on.
Table VII. Results summary for the simulated MS-based proteomic pipeline
Performance indices Median values
Peptide identification rate 0.17
Protein quantification rate 0.54
Protein quantification error 0.67
Percentage of detected markers 52%
LDA error on the original protein data 0.01
KNN error on the original protein data 0.03
LDA error on the observed protein data 0.18
KNN error on the observed protein data 0.24
D. Discussion
The main observations that were gleaned from the results of this study are as follows.
• Regarding sample characteristics, we observed a positive correlation between
peptide efficiency and performance. The intricacy in detecting low-abundance
peptides was demonstrated, thereby elucidating the advantage of sample frac-
tionation and protein depletion through immunoaffinity-based approaches. More-
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over, we showed that results could be improved by increasing sample size.
• As for instrument characteristics, the compound effects of instrument response
and saturation were first examined and it was shown that the effectiveness of
MS in quantitative analysis relies on achieving a wide linear dynamic range
with a high saturation ceiling and matching instrument sensitivity. Enhanc-
ing gas-phase analyte charging, facilitating droplet evaporation, or introducing
ionization competitors can be beneficial in extending the linear dynamic range.
The adverse effects of noise was illustrated, highlighting the need in strictly
following experiment protocols to minimize variance and measurement error.
• Peptide detection and experimental design characteristics were also studied. It
was shown that improving peptide detection algorithms in the direction of en-
hancing true positive rate for a wide range of SNR (especially for low SNR) and
tackling convoluted peptide signals could be invaluable, especially for complex
samples and for MS instruments with limited mass resolution. It was also ob-
served that the use of only a small number of replicate tandem MS assays could
effectively reduce the MS2 under-sampling problem and improve performance.
To enable the performance analysis of such a complex system, many reasonable
assumptions are made and the pipeline is simplified and reduced to a few key charac-
teristics; nevertheless corruption of the true signal caused by the pipeline is evident
and readily seen. This is expected to become worse as more steps are considered.
Though we used two sample types to illustrate the use of the LC-MS based
pipeline model, the extension to multiple sample types is straightforward. In addition,
the same methodology can be applied to study other MS platforms such as matrix-




MODEL-BASED STUDY OF MISSING VALUE IMPUTATION AND
CLASSIFICATION IN DNA MICROARRAY DATA∗
A. Introduction
Missing values (MVs) and low quality data points are frequently observed in microar-
ray data. Many imputation methods have been proposed for estimating MVs in gene
expression data which are usually organized in a matrix form with rows corresponding
to the gene probes and columns representing the arrays. Trivial methods to deal with
MVs in the microarray data matrix include replacing the MV by zero (given the data
is in log domain) or by row average (RAVG). These methods do not make use of the
underlying correlation structure of the data and thus often perform poorly in terms of
estimation accuracy. Better imputation techniques have been developed to estimate
the MVs by exploiting the observed data structure and expression pattern. These
methods include K-nearest Neighbor imputation (KNNimpute) and singular value
decomposition (SVD) based imputation [84], Bayesian principal components analysis
(BPCA) [85], least square regression based imputation [86], local least squares im-
putation (LLS) [87], and LinCmb imputation [88], in which the MV is calculated by
a convex combination of the estimates given by several existing imputation meth-
ods, namely, RAVG, KNNimpute, SVD and BPCA. In addition, a nonlinear PCA
imputation based on neural networks was proposed for effectively dealing with non-
linearly structured microarray data [89]. Gene ontology based imputation utilizes
∗Reprinted with permission from “Impact of missing value imputation on classi-
fication for DNA microarray gene-expression data: a model-based study” by Y. Sun,
U. M. Braga-Neto, and E. R. Dougherty, EURASIP Journal of Bioinformatics and
Systems Biology, vol.50, 17 pages, 2009, Copyright 2009 by SpringerOpen.
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information on functional similarities to facilitate the selection of relevant genes for
MV estimation [90]. Integrative MV estimation method (iMISS) aims at improving
the MV estimation for data sets with limited numbers of samples by incorporating
information from multiple microarray data sets [91].
In most of the studies about MV imputation, the performance of various impu-
tation algorithms is compared in terms of the normalized root mean squared error
(NRMSE) [84], which measures how close the imputed value is to the original value.
However the problem is that the original value is unknown for the missing data,
thus calculating NRMSE is infeasible in practice. To circumvent this problem, all the
studies involving NRMSE calculation adopted the following scheme [84,86–88,91–93]:
First, a sub-complete matrix is extracted from the original MV-contained gene expres-
sion matrix; Then, entries of the complete matrix are randomly removed to generate
the artificial MVs; Finally, MV imputation is applied. The NRMSE can now be cal-
culated to measure the imputation accuracy, since the original values are now known.
This method is problematic for two reasons. First, the selection of artificial missing
entries is random, and thus is independent of the data quality — whereas imputing
data spots with low quality is the main scenario in real world. Secondly, in the cal-
culation of the NRMSE, the imputed value is compared against the original, but the
original is actually a noised version of the true signal value, and not the true value
itself.
While much attention has been paid to the imputation accuracy measured by
the NRMSE, a few studies have examined the effect of imputation on high-level
analyses (such as biomarker identification, sample classification, and gene clustering),
which demand that the data set be complete. For example, the effect of imputation
on the selection of differentially expressed genes is examined in [88, 93, 94] and the
effect of KNN imputation on hierarchical clustering is considered in [38], where it it
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is shown that even a small portion of MVs can considerably decrease the stability
of gene clusters and stability can be enhanced by applying KNN imputation. The
effects of various MV imputation methods on the gene clusters produced by the
K-means clustering algorithm are examined in [95], the main findings being that
advanced imputation methods such as KNNimpute, BPCA and LLS yield similar
clustering results, although the imputation accuracies are noticeably different in terms
of NRMSE. To our knowledge, only two studies have investigated the relationship
between MV imputation of microarray data and classification accuracy.
Wang et al. study the effects of MVs and their imputation on classification perfor-
mance and report no significant difference in the classification accuracy results when
KNNimpute, BPCA, or LLS are applied [96]. Five data sets are used: a lymphoma
dataset with 20 samples, a breast cancer dataset with 59 samples, a gastric cancer
dataset with 132 samples, a liver cancer dataset with 156 samples, and a prostate
cancer dataset with 112 samples. The authors consider how differing amounts of
MVs may affect classification accuracy for a given dataset, but rather than using
the true MV rate, they use the MV rate threshold (MVthld) throughout their study,
where, for a given MVthld (MVthld = 5n%, where n = 0, 1, 2, 4, 6, 8), the genes with
MV rate less then MVthld are retained to design the classifiers. As a result, the true
MV rate (which is not reported) of the remaining genes does not equal MVthld and,
in fact, can be much less than MVthld. Hence, the parameter MVthld may not be
a good indicator. Moreover, the authors plot the classification accuracies against a
number of values for MVthld, but as MVthld increases, the number of genes retained
to design the classifier becomes larger and larger, so that the increase or decrease
in the classification accuracy may be largely due to the additional included genes
(especially if the genes are marker genes) and may only weakly depend on MVthld.
This might explain the non-monotonicity and the lack of general trends in most of
94
the plots.
By studying two real cancer datasets (SRBCT dataset with 83 samples of 4 tumor
types, GLIOMA dataset with 50 samples of 4 glioma types), Shi et al. report that the
gaps between different imputation methods in terms of classification accuracy increase
as the MV rate increases [97]. They test 5 imputation methods (RAVG, KNNimpute,
SKNN, ILLS, BPCA ), 4 filter-type feature selection methods (t-test, F-test, cluster-
based t-test and cluster based F-test) and 2 classifiers(5NN and LSVM). They have
two main findings: (1) when the MV rate is small (≤= 5%), all imputed datasets
give similar classification accuracies that are close to that of the original complete
dataset; however, the classification performances given by different datasets diverge
as the MV rate increases; and (2) datasets imputed by advanced imputation methods
(e.g. BPCA) can reach the same classification accuracy as the original dataset. A
fundamental problem with their experimental design is that the MVs are randomly
generated on the original complete dataset, which is extracted from the MV-contained
gene expression matrix. Although this randomized MV generating scheme is widely
used, it ignores the underlying data quality.
A critical problem within both aforementioned studies is that all training data
and test data are imputed together before classifier design and cross-validation is
adopted for the classification process. The test data influences the training data
in the imputation stage and the influence is passed to the classifier design stage.
Therefore, the test data is involved in the classification design process, which violates
the principle of cross-validation.
In this paper, we carry out a model-based analysis to investigate how different
properties of a dataset influence imputation and classification, and how imputation
affects classification performance. We compare six popular imputation algorithms,
namely RAVG, KNNimpute, LLS.L2, LLS.PC, LS and BPCA, by measuring how
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well the imputed dataset can preserve the discriminant power residing in the original
dataset. An empirical analysis using real data from cancer microarray studies is also
carried out. In addition, the NRMSE-based comparison is included in the study,
with a modification in the case of the synthetic data to give an accurate measure.
Recommendations for the application of various imputations under different situations
are given in the Results section.
B. Methods
1. Model for synthetic data
Many studies have shown the log-normal property of microarray data, that is, the
distribution of log-transformed gene expression data approximates a normal distri-
bution [98, 99]. In addition, biological effects which are generally assumed to be
multiplicative in the linear scale become additive in the log scale, which simpli-
fies data analysis. Thus, the ANOVA model [3, 100] is widely used, in which the
log-transformed gene expression data are represented by a true signal plus multiple
sources of additive noise.
There are other models proposed for gene expression data, including a multi-
plicative model for gene intensities [101]; a hierarchical model for normalized log
ratios [102]; and a binary model [103]. The first two of these models do not take
gene-gene correlation into account. In addition, the second model does not model the
error sources. The binary model is too simplistic and not sufficient for the MV study
in this paper.
Based on the log-normal property and inspired by ANOVA, we propose a model
for the normalized log-ratio gene expression data which is centered at zero, assuming
that any systematic dependencies of the log-ratio values on intensities have been
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removed by methods such as Lowess [104, 105]. Here, we consider two experimental
conditions for the microarray samples (e.g., mutant versus wild-type, diseased versus
normal). The model can be easily extended to deal with multiple conditions as well.
Let X be the gene expression matrix with m genes (rows) and n array samples
(columns). xij denotes the log-ratio of expression intensity of gene i in sample j to
the intensity of the same gene in the baseline sample. xij consists of the true signal
sij plus additive noise eij:
xij = sij + eij. (5.1)
The true signal is given by
sij = rij + uij, (5.2)
where rij represents the log-transformed fold change and uij is a term introduced to
create correlation among the genes.
The log-transformed fold-change rij is given by:
rij =

ai, if gene i is up-regulated in sample j,
0, if gene i is equal to the baseline in sample j,
−bi, if gene i is down-regulated in sample j,
(5.3)
under the constraint that rij is constant across all the samples in the same class.
The parameters ai and bi are picked from a univariate Gaussian distribution, ai, bi ∼
Normal(µr, σ
2
r), where the mean log-transformed fold change µr is set to 0.58, cor-
responding to a 1.5 fold change in the original linear scale, as this is a level of fold
change that can be reliably detected [101]. The standard deviation of log-transformed
fold change σr is set to 0.1.
The distribution of uij is multivariate Gaussian with mean 0 and covariance
97
matrix Σ. A block-based structure [69] is used for the covariance matrix to reflect
the interactions among gene clusters. Genes within the same block (e.g. genes belong
to the same pathway) are correlated with correlation coefficient ρ and genes within
different blocks are uncorrelated as given by the following equation:
Σ = σ2u

Σρ 0 · · · 0
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In the above equations, the gene block standard deviation σu, correlation ρ, and size
D are tunable parameters, the values of which are specified in the Results section.
The additive noise eij in Eq. 5.1 is assumed to be zero-mean Gaussian, eij ∼
Normal(0, σ2i ). The standard deviation σi varies from gene to gene and is drawn
from an exponential distribution with mean µe to account for the non-homogeneous
missing value distribution generally observed in real data [106]. The noise level µe is
a tunable parameter, the value of which is specified in the Results section.
Following the model above, we generate synthetic gene expression datasets for
the true signal, S, and the observed expression values, X. In addition, the dataset





xij, if |eij| < τ
MV, o.w.
(5.6)
The threshold τ is adjusted to give varying rates of missing values in the simulated
dataset, as discussed in the Results section.
2. Imputation methods
Following the notation of [107], a gene with MVs to be estimated is called a target
gene, with expression values across array samples denoted by the vector yi. The





The set of genes used to estimate ymisi forms the candidate gene set Ci for yi. Ci is
partitioned into Cmisi and C
obs
i according to the observable and the missing indexes
of yi. In row average imputation (RAVG), the MVs of the target gene yi are simply
replaced by the average of observed values, i.e. Mean(yobsi ).
We will discuss three more complex methods, namely KNNimpute, LLS, and LS
imputation, which follow the same two basic steps:
1) For each target gene yi, K genes with expression profiles most similar to the
target gene are selected to form the candidate gene set Ci = [xp1 ,xp2 , · · · ,xpK ]T .
2) The missing part of the target gene ymisi is estimated by a weighted combi-
nation of the corresponding K candidate genes xp1 ,xp2 , · · · ,xpK . The weights are
calculated in different manners for different imputation methods.
We will additionally describe briefly the BPCA imputation method.
a. K-nearest neighbor imputation (KNNimpute)
In the first step, the L2 norm is employed as the similarity measure for selecting
the K neighbor genes (candidate genes). In the second step, the missing part of
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the target gene (ymisi ) is estimated as a weighted average (convex combination) of
the corresponding parts of the candidate genes (xmispl , l = 1, 2, · · · , K ) which are not








The weight for each candidate gene is proportional to the reciprocal of the L2 distance




















‖yobsi − xobspl ‖2
, l = 1, 2, . . . , K. (5.9)
The performance of KNNimpute is closely associated with the number of neigh-
bors K used. A value of K within the range of 10-20 was empirically recommended,
while the performance (in terms of NRMSE) degraded when K was either too small
or too large [84]. We use the default value of K = 10 in the Results section.
b. Local least squares imputation (LLS)
In the first step, either the L2 norm or the absolute value of the Pearson correlation
coefficient is employed as the similarity measure for selecting the K candidate genes
[87], resulting in two different imputation methods LLS.L2 and LLS.PC, respectively,
with the former reported to perform slightly better than the latter. Owing to the
similarity of performance, for clarity of presentation we only show LLS.L2 in the
results section (the full results including LLS.PC are given on the companion website).
100
In the second step, the missing part of the target gene is estimated as a linear
combination (which need not be a convex combination) of the corresponding parts of












where the vector of weights w = [w1, w2, . . . , wK ]
T solves the least squares problem
min
w
∥∥∥(Cobsi )T w − yobsi ∥∥∥
2
. (5.11)






where A† denotes the pseudo-inverse of matrix A.
c. Least squares imputation (LS)
In the first step, similar to LLS.PC, the K most correlated genes are selected based
on their absolute correlation to the target gene [86].
In the second step, the least squares estimate of the target given each of the K
candidate gene is obtained:
yˆi,l = y¯i + βl(xpl − x¯pl), l = 1, . . . , K , (5.13)





where cov(yi,xpl) denotes the sample covariance between the target yi and the can-
didate xpl and var(xpl) is the sample variance of the candidate xpl .
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The missing part of the target gene is then approximated by a convex combina-













1− corr(yi,xpl)2 + 10−6
)2
(5.16)




d. Bayesian principal component analysis (BPCA)
BPCA is built upon a probabilistic PCA model and employs a variational Bayes algo-
rithm to iteratively estimate the posterior distribution for both the model parameters
and the MVs until convergence. The algorithm consists of three primary processes,
which are (1) principle component regression, (2) Bayesian estimation, and (3) an
expectation-maximization-like repetitive algorithm [85]. The principal components
of the gene expression covariance matrix are included in the model parameters, and
redundant principal components can be automatically suppressed by using an auto-
matic relevance determination (ARD) prior in the Bayes estimation. Therefore, there
is no need to choose the number of principal components one want to use, and the




Based on the previously described data model, we generate various synthetic microar-
ray datasets by changing the values of the model parameters, corresponding to various
noise levels, gene correlations, MV rates, and so on (more details are given in the Re-
sults Section). The MVs are determined by Eq. 5.6, with the threshold τ adjusted
to give a desired MV rate. For each of the models, the simulation is repeated 150
times. In each repetition, according to Eq. 5.1 and Eq. 5.2, the true signal dataset,
S, and the measured-expression dataset, X, are first generated. The dataset XMV
with missing values is then generated based on the data quality of X and a given
MV rate. Next, six3 imputation algorithms, namely RAVG, KNNimpute, LLS.L2,
LLS.PC, LS and BPCA are applied separately to calculate the MVs, yielding six
imputed datasets, Xk, for k = 1, . . . , 6. Each of these training datasets contains m
genes and nr array samples and is used to train a number of classifiers separately. For
each k, a measured-expression test dataset U and a missing value dataset UMV are
generated independently of, but in an identical fashion to, the datasets X and XMV ,
respectively. Each of these test sets contains m genes and nt array samples, nt being
large in order to achieve a very precise estimate of the actual classification error.
A critical issue concerns the manner in which the test data are employed. As
noted in the Introduction, imputation cannot be applied to the training and test
data as a whole. Not only does this make the designed classifier dependent on the
test data, it also does not reflect the manner in which the classifier will be employed.
Testing involves a single new example, independent of the training data, being labeled
by the designed classifier. Thus, error estimation proceeds in the following manner
after imputation has been applied to the training data and a classifier designed from
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the original and imputed values: (1) an example U ∈ U is selected and adjoined to
the measured-expression training set X; (2) missing values are generated to form the
set (X ∪ U)MV [note that (X ∪ U)MV = XMV ∪ UMV ]; (3) imputation is applied
to (X ∪ U)MV , the purpose being to utilize the training data in the imputation for
UMV to obtain the complete vector U IMP (the superscript IMP means one impu-
tation method); (4) the designed classifier is applied to U IMP and the error (0 or
1) recorded; (5) the procedure is repeated for all test points; and (6) the estimated
error is the total number of errors divided by nt. Notice that the training data are
used in the imputation for the newly observed example, which is part of the classi-
fier. The classifier consists of imputation for the newly observed example following
by application of the classifier decision procedure, which has been designed on the
training data, independently of the testing example. Overall, the classifier operates
on the test example in a manner determined independently of the test example. If the
imputation for the test data were independent of the training data, then one would
not have to consider imputation as part of the classification rule; however, when the
imputation for the test data is dependent on the training data, it must be considered
part of the classification rule.
The classifier training process includes feature selection and classifier design
based on a given classification rule. Three popular classification rules are used in
this paper: Linear Discriminant Analysis (LDA), 3-Nearest Neighbor (3NN) and Lin-
ear Support Vector Machine (LSVM) [55]. Two feature selection methods, t-test
and sequential forward floating search (SFFS) [108], are considered in our simulation
study. The former is a typical filter method (i.e., it is classifier-independent) while
the latter is a standard procedure used in the wrapper method (i.e., it is associated
with classifier design and is thus classifier-specific). SFFS is a development of the
sequential forward selection(SFS) method. Starting with an empty set A, SFS iter-
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atively adds new features to A, so that the new set A ∪ {fa} is the best (gives the
lowest classification error) among all A∪{f}, f /∈ A. The problem with SFS is that a
feature added to A early may not work well in combination with others but it cannot
be removed from A. SFFS can mitigate the problem by “looking-back” for the fea-
tures already in set A. A feature is removed from A if A−{fr} is the best among all
A− {f}, f ∈ A, unless fr, called the ”least significant feature”, is the most recently
added feature. This exclusion continues, one feature at a time, as long as the feature
set resulting from removal of the least significant feature is better than the feature
set of the same size found earlier in the SFFS procedure [109]. For the wrapper
method SFFS, we use bolstered error estimation [110]. In addition, considering the
intense computation load requested by SFFS in the high-dimension problems such as
microarray classification, a two-stage feature selection algorithm is adopted, in which
the t-test is applied in the first stage to remove most of the noninformative features
and then SFFS is used in the second stage [69]. This two-stage scheme takes advan-
tage of both the filter method and the wrapper method and may even find a better
feature subset than directly applying the wrapper method to the full feature set [111].
In summary, for each of the data models, 8 pairs of training and testing datasets are
generated and are evaluated by a combination of 2 feature selection algorithms and
3 classification rules, resulting in a very large number of experiments.
Each experiment is repeated 150 times, and the average classification error is
recorded. The averaged classification error plots for different datasets, feature se-
lection methods and classification rules are shown in the Results section. Besides
the classification errors, the NRMSE between the signal dataset and each of the 6




























Fig. 21. Simulation flow chart
As previously mentioned, there can be drawbacks associated with the NRMSE
calculation; however, in our simulation study, the MVs are marked according to the
data quality and the NRMSE is calculated based on the true signal dataset which






In this way, the aforementioned drawbacks about using NRMSE are addressed.
b. Patient data
In addition to the synthetic data described in the previous section, we used the two
following publicly-available data sets from published studies:
• Breast cancer dataset (BREAST): Tumor samples from 295 patients with
primary breast carcinomas were studied by using inkjet-synthesized oligonu-
cleotide microarrays which contained 24,479 oligonucleotides probes along with
1281 control probes [112]. The samples are labeled into two groups [113] : 180
samples for poor-prognosis signature group, and 115 samples for good-prognosis
signature. In addition to the log-ratio gene expression data, the log error data
is also available which can be used to assess the data quality.
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• Prostate cancer dataset (PROST): Samples of 71 prostate tumors and
41 normal prostate tissues were studied, using cDNA microarray containing
26,260 different genes [114]. In addition to the log-ratio gene expression data,
additional information such as background (foreground) intensities and SD of
foreground and background pixel intensities are also available and thus can be
used to calculate the log error according to the Rosetta error model [115] — the





















Ik(i, j) = Ik,fg(i, j)− Ik,bg(i, j), k = 1, 2. (5.19)
In the above equations, k specifies the red or green channel in the two-dye ex-
periment, σk,fg(i, j) and σk,bg(i, j) denote the SD of foreground and background
pixels, respectively, of the i-th probe in the j-th microarray sample, Nk,fg and
Nk,bg are the numbers of pixels used in the mean foreground and background
calculation, respectively, and Ik,fg and Ik,bg are the mean foreground and back-
ground intensities, respectively.
For the patient data study, the schemes used for imputation, feature selection
and classification are similar to those applied in the synthetic data simulation, except
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that we use hold-out-based error estimation, i.e. in each repetition, nr samples are
randomly chosen from all the samples as the training data and the remaining nt =
n−nr samples are used to test the trained classifiers, with nt being much larger than nr
in order to make error estimation precise. We preprocess the data by removing genes
which have an unknown or invalid data value in at least one sample (flagged manually
and by the processing software). After this preprocessing step, the dataset is complete,
with all data values being known. We further preprocess the data by filtering out
genes whose expressions do not vary much across all the array samples [95] [114];
indeed, the genes with small expression variance do not have much discrimination
power for classification and thus are unlikely to be selected by any feature selection
algorithm [97]. The resulting feature sizes are 400 and 500 genes for the prostate and
the breast dataset, respectively. It is at this point where we begin our experimental
process by generating the MVs.
Unlike the synthetic study, the true signal dataset is unknown in the patient
data study since the data values are always contaminated by measurement errors.
Therefore, in the absence of the true signal dataset, the NRMSE is calculated between
the measured dataset and each of the imputed datasets (which is the usual procedure
adopted in the literature). Thus the NRMSE result is less reliable in the patient data
study, which highlights further the need for evaluating imputation on the basis of
other factors, such as classification performance.
C. Results
1. Results for the synthetic data
We have considered the model described in the previous section, for different combi-
nations of parameters, which are displayed in Table VIII. In addition, since the signal
108
dataset is noise-free, the classification performance given by the signal dataset can
serve as a benchmark. In the other direction, the benefit of an imputation algorithm
is determined by how well imputation improves the classification accuracy of the mea-
sured dataset. The classification errors of the true signal dataset, measured dataset,
and imputed datasets under different data distributions are shown in figures 22-27.
The full set of figures is given on the companion website. It should be recognized that
the figures are meant to illustrate certain effects and that other model parameters are
fixed while the effects of changing a particular parameter are studied.
Table VIII. Simulation summary for the microarray data analysis pipeline
Parameters/methods Values/descriptions
Gene block standard deviation σu = 0.3, 0.4, 0.5
Gene block correlation ρ = 0.5, 0.7
Gene block size D = 15
Noise level µe = 0.2, 0.3, 0.4
MV rate r = 1, 5, 10, 15%
No. of marker genes 30
No. of total genes 500
Training sample size 60
Testing sample size 200
No. of repetitions for each model 150
Imputation algorithms RAVG, KNN, LLS.L2, LLS.PC, LS, BPCA
Classification rules LDA, 3NN, SVM
Feature selection methods t-test,SFFS
a. Effect of noise level
Fig. 22 shows the impact of noise level (parameter µe in the data model) on imputation
and classification. When noise level goes up (from left to right along the y-axis), the
classification errors (along with the Bayes errors) of the measured dataset and the
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imputed datasets all increase as expected; the classification errors of the signal dataset
stay nearly the same and are consistently the smallest among all the datasets, since the
signal dataset is noise-free. Relative to the signal dataset benchmark, the classification
performances of imputed datasets deteriorate less than that of the measured dataset as
the noise level increases, although their performances degrade with increasing noise.
For the smallest noise level, imputation does little to improve upon the measured
dataset.
b. Effect of variance
The effect of variance (parameter σu in the data model) on imputation and classi-
fication is shown in Fig. 23. As the variance increases, the classification errors of
all datasets increase as expected. When the variance is small (e.g. σu = 0.3), all
imputed datasets outperform the measured dataset consistently across all the com-
binations of feature selection methods and classification rules; however, when the
variance is relatively large (e.g. σu = 0.5), the measured dataset catches up with and
may outperform the datasets imputed by less advanced imputation methods, such as
RAVG and KNNimpute. As variance increases, the discriminant power residing in
the data is weakened, and the underlying data structure becomes more complex (as
confirmed by computing the entropy of the eigenvalues of the covariance matrix of
the gene expression matrix [92], data not shown). Thus it becomes harder for the
imputation algorithms to estimate the MVs.
In addition, it is observed that the classification performance of one imputed
dataset may outperform that of the other imputed dataset for a certain combination
of feature-selection method and classification rule, while the performances of the two
may reverse for another combination of feature selection and classification rule. For
instance, when the classification rule is LDA and the feature selection method is t-
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Fig. 22. Effect of noise level. The classification error of the signal dataset (signal),
the measured dataset (orgn), and the five imputed datasets. The underlying
distribution parameters are: SD σu = 0.4, gene correlation ρ = 0.7, MV rate
r = 10%. Each panel in the figure corresponds to one combination of the
feature selection methods and the classification rules, which is given by the
title. The x-axis labels the number of selected genes, the y-axis is the noise
level, and the z-axis is the classification error.
111
test, the BPCA imputed dataset outperforms the LLS.L2 imputed dataset; however,
the latter outperforms the former when the feature selection method is SFFS and the
same classification rule is used (plots on companion website). This suggests that a
certain combination of feature-selection method and classification rule may favor one
imputation method over another.
c. Effect of correlation
Fig. 24 illustrates the effect of gene correlation (parameter ρ in the data model) on
imputation and classification. As the gene correlation goes up, the classification errors
of all datasets increase as expected. Although it is not straightforward to compare
the classification performances of different datasets under different correlations, we
notice that the correlation-based MV imputation methods such as LLS.PC and LS
may slightly outperform BPCA in larger correlation cases, suggesting that the local
correlation structure of a dataset may be better captured by such methods.
d. Effect of MV rate
Perhaps the most important observations concern the missing value rate, which is
determined by adjusting the parameter τ in Eq. 5.6 to obtain a specified percentage
r of missing values: r = 1, 5, 10, 15, 20, 25%. Because we wish to show the effects
of two model parameters, we will limit ourselves in the paper to considering 3NN
and SVM with t-test feature selection. Corresponding results for other cases are on
the companion website. Figures 25, 26, and 27 provide the results for the signal
standard deviation σu = 0.3, 0.4, and 0.5, respectively, with parts a, b, and c of each
figure corresponding to noise levels µe = 0.2, 0.2, 0.3, 0.3, and 0.4, 0.4, respectively.
In all cases, ρ = 0.7. In Fig. 25(a), we observe the following phenomenon: there
is improvement on the performance of the various imputation methods as the MV
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Fig. 23. Effect of variance. The classification error of the signal dataset (signal), the
measured dataset (orgn), and the five imputed datasets. The underlying
distribution parameters are: noise level µe = 0.2, gene correlation ρ = 0.7,
MV rate r = 15%. Each panel in the figure corresponds to one combination
of the feature selection methods and the classification rules, which is given
by the title. The x-axis labels the number of selected genes, the y-axis is the
signal SD, and the z-axis is the classification error.
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Fig. 24. Effect of correlation. The classification error of the signal dataset (signal),
the measured dataset (orgn), and the five imputed datasets. The underlying
distribution parameters are: SD σu = 0.5, noise level µe = 0.2, MV rate
r = 10%. Each panel in the figure corresponds to one combination of the
feature selection methods and the classification rules, which is given by the
title. The x-axis labels the number of selected genes, the y-axis is the gene
correlation strength, and the z-axis is the classification error.
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rate initially increases, and then performance deteriorates (quickly, in some cases),
as the MV rate continues to increase after a certain point. We shall refer to this
phenomenon as the missing-value rate peaking phenomenon. It is important to stress
that degradation of performance of imputation at larger MV rates is quite noticeable:
at 20% the weaker imputation methods perform worse than the measured data and
at 25% imputation is detrimental for kNN and not helpful for SVM. In Fig. 25(b)
we again observe the MV rate peaking phenomenon; however, imputation performs
better relative to the measured data. Imputation remains better throughout for SVM
and only gets worse for kNN at MV rate 25%. In Fig. 25(c), the peaking phenomenon
is again noticeable, but for this noise level imputation is much better relative to the
measured data and all imputation methods remain better at all MV rates. Similar
trends are observed in figures 26 and 27, the difference being that as σu increases from
0.3 to 0.4 and 0.5, the imputation methods perform increasingly worse with respect
to the measured data. Note particularly the degraded performance of the simpler
imputation schemes.
Fig. 28 displays the behavior of NRMSE as a function of MV rate. Here, we
also observe a peaking phenomenon for the NRMSE, though a modest one. This is
in contrast to previous studies, which all generally report the NRMSE to increase
monotonically with increasing MV rate [86, 87, 91, 95]; this may be a consequence of
the different way in which the MVs are selected in those studies as compared with
the present one; in the former, MVs are picked randomly, whereas in the latter, MVs
are picked based on quality considerations, revealing the peaking phenomenon.
2. Results for the patient data
For the patient data, since the true signal is unknown, we only conduct the comparison
of imputations with respect to different MV rates. The effect of MV rate is shown in
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Figure 5: Eﬀect of MV Rate. The classification error of the signal dataset (signal), the measured dataset (orgn), and the five imputed datasets.
The underlying distribution parameters are SD σu = 0.3, gene correlation ρ = 0.7, and noise level μe = 0.2, 0.2, 0.3, 0.3, 0.4, 0.4 for subfigures
(a), (b), (c), (d), (e), and (f), respectively. The x-axis labels the number of selected genes, the y-axis is the MV rate, and the z-axis is the
classification error.
Fig. 25. ffect of MV Rate. The classificatio error of the sig al dataset (signal),
the measured dataset (orgn), and the five imputed datasets. The underlying
distribution parameters are: SD σu = 0.3, gene correlation ρ = 0.7 and noise
level µe = 0.2, 0.2, 0.3, 0.3, 0.4, 0.4 for subfigures (a)-(f), respectively. The
x-axis labels the number of selected genes, the y-axis is the MV rate, and the
z-axis is the classification error.
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Figure 6: Eﬀect of MV Rate. The classification error of the signal dataset (signal), the measured dataset (orgn), and the five imputed datasets.
The underlying distribution parameters are SD σu = 0.4, gene correlation ρ = 0.7, and noise level μe = 0.2, 0.2, 0.3, 0.3, 0.4, 0.4 for subfigures
(a), (b), (c), (d), (e), and (f), respectively. The x-axis labels the number of selected genes, the y-axis is the MV rate, and the z-axis is the
classification error.
Fig. 26. ffect of MV Rate. The classifica io error of the si l dataset (signal),
the measured dataset (orgn), and the five imputed datasets. The underlying
distribution parameters are: SD σu = 0.4, gene correlation ρ = 0.7 and noise
level µe = 0.2, 0.2, 0.3, 0.3, 0.4, 0.4 for subfigures (a)-(f), respectively. The
x-axis labels the number of selected genes, the y-axis is the MV rate, and the
z-axis is the classification error.
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Figure 7: Eﬀect of MV Rate. The classification error of the signal dataset (signal), the measured dataset (orgn), and the five imputed datasets.
The underlying distribution parameters are SD σu = 0.5, gene correlation ρ = 0.7, and noise level μe = 0.2, 0.2, 0.3, 0.3, 0.4, 0.4 for subfigures
(a), (b), (c), (d), (e), and (f), respectively. The x-axis labels the number of selected genes, the y-axis is the MV rate, and the z-axis is the
classification error.
Fig. 27. Effect of MV Rate. The classification error of the signal dataset (signal),
the measured dat set (orgn), and the five imputed datasets. The underlying
distribution parameters are: SD σu = 0.5, gene correlation ρ = 0.7 and noise
level µe = 0.2, 0.2, 0.3, 0.3, 0.4, 0.4 for subfigures (a)-(f), respectively. The
x-axis labels the number of selected genes, the y-axis is the MV rate, and the
z-axis is the classification error.
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Fig. 28. The NRMSE values (y-axis) of the five imputation algorithms with respect
to the MV rate (x-axis). The underlying distribution parameters are: SD
σu = 0.5, noise level µe = 0.2, gene correlation ρ = 0.7.
119
figures 29 and 30, for the BREAST and the PROST dataset, respectively. The trends
observed are similar to those in the synthetic data study, in the sense that there is
a degradation of performance of imputation methods with increasing MV rates. On
the other hand, the missing-value rate peaking phenomenon is less evident here, but
still present, as can be seen from the fact that the classification performance of LLS,
LS and BPCA imputed datasets in a few cases becomes better under a larger MV
rate than the corresponding datasets with a smaller MV rate.
It is again observed that the classification performances of imputed datasets
depend on the underlying combination of feature selection method and classification
rule. For example, RAVG and KNNimpute show satisfactory performances for the
combinations SFFS+LDA and Ttest+LDA (data not shown), but perform relatively
poorly for the other combinations.
The NRMSE values of different imputation methods generally decrease first and
then increase as the MV rate increases (see Fig. 31) which is similar to the trend
observed in synthetic data study.
It is also found that there is no strong correlation between the low-level per-
formance measure NRMSE and the high-level measure classification error. A small
NRMSE may not necessarily suggest a small classification error, i.e. an imputation
method may perform better than another imputation method in terms of estimation
accuracy, but the former may not be as good as the latter in terms of classification per-
formance. In other words, although a given imputation method may be more accurate
than another when measured by NRMSE, it might decrease more the discrimination










































































































Fig. 29. The classification errors of the measured prostate cancer dataset (orgn), and
the five imputed datasets. Each panel in the figure corresponds to one com-
bination of the feature selection methods and the classification rules, which is
given by the title. The x-axis labels the number of selected genes, the y-axis












































































































Fig. 30. The classification errors of the measured breast cancer dataset (orgn), and
the five imputed datasets. The meanings of the axes and titles are the same
as in the previous figure.
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Fig. 31. The NRMSE values (y-axis) of the five imputation algorithms with respect to
the MV rate (x-axis) for the PROST dataset and the BREAST dataset.
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